,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,OPALIN,"HTMP10, TMEM10, TMP10",ENSG00000197430,Oligodendrocytic myelin paranodal and inner loop protein,10,96343216-96359365,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014372,Supported,,,,,Tissue enriched,Tissue enriched,864,cerebral cortex: 86.3,all non-specific tissues: 0.0,Not detected,,
1,GFAP,FLJ45472,ENSG00000131095,Glial fibrillary acidic protein,17,44903161-44916937,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000039, HPA056030, HPA063513",Enhanced,Supported,Supported,Intermediate filaments,,Tissue enriched,Tissue enriched,398,cerebral cortex: 3768.4,bone marrow: 9.4,Mixed,,
2,OMG,OMGP,ENSG00000126861,Oligodendrocyte myelin glycoprotein,17,31272013-31297539,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA008206, HPA012693",Enhanced,,,,,Group enriched,Tissue enriched,318,cerebral cortex: 137.4,bone marrow: 0.4,Not detected,,
3,OLIG2,"BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17",ENSG00000205927,Oligodendrocyte transcription factor 2,21,33025845-33029196,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003254, CAB019381",Enhanced,,Uncertain,Nucleoplasm<br>Plasma membrane,,Tissue enriched,Tissue enriched,245,cerebral cortex: 91.0,duodenum: 0.3,Cell line enhanced,,HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9
4,GRIN1,"GluN1, NMDAR1",ENSG00000176884,Glutamate ionotropic receptor NMDA type subunit 1,9,137138390-137168762,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters",Evidence at protein level,CAB006831,Approved,,,,,Mixed,Tissue enriched,208,cerebral cortex: 151.8,prostate: 0.7,Cell line enhanced,,RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2
5,NEUROD6,"Atoh2, bHLHa2, Math-2, Nex1, NEX1M",ENSG00000164600,Neuronal differentiation 6,7,31337461-31340894,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA027046, HPA074530",Enhanced,Approved,,,,Not detected,Tissue enriched,180,cerebral cortex: 18.0,all non-specific tissues: 0.0,Cell line enriched,71.0,SCLC-21H: 7.0
6,SLC17A7,"BNPI, VGLUT1",ENSG00000104888,Solute carrier family 17 member 7,19,49429401-49442360,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB037183, HPA050458, HPA063679",Enhanced,Supported,,,,Tissue enriched,Tissue enriched,177,cerebral cortex: 584.4,adipose tissue: 3.3,Cell line enhanced,,HMC-1: 18.2;K-562: 6.2;SCLC-21H: 5.7
7,CREG2,,ENSG00000175874,Cellular repressor of E1A stimulated genes 2,2,101345551-101387595,Predicted secreted proteins,Evidence at protein level,HPA038224,Enhanced,,,,,Mixed,Tissue enriched,164,cerebral cortex: 90.9,fallopian tube: 0.5,Cell line enhanced,,CACO-2: 2.0;HaCaT: 5.6;HeLa: 1.6;PC-3: 2.3
8,NEUROD2,"bHLHa1, NDRF",ENSG00000171532,Neuronal differentiation 2,17,39603536-39609777,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,142,cerebral cortex: 14.9,stomach: 0.1,Cell line enriched,302.0,SCLC-21H: 30.2
9,C1orf61,CROC4,ENSG00000125462,Chromosome 1 open reading frame 61,1,156404250-156430701,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,129,cerebral cortex: 504.3,testis: 3.9,Cell line enriched,9.0,BEWO: 12.5
10,KCNJ9,"GIRK3, Kir3.3",ENSG00000162728,Potassium voltage-gated channel subfamily J member 9,1,160081570-160090563,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA070478,Enhanced,,,,,Tissue enriched,Tissue enriched,113,cerebral cortex: 52.3,"adrenal gland,testis: 0.4",Not detected,,
11,ZDHHC22,C14orf59,ENSG00000177108,Zinc finger DHHC-type containing 22,14,77131270-77142734,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049471, HPA072213",,,Enhanced,Plasma membrane,,Tissue enriched,Tissue enriched,113,cerebral cortex: 64.2,testis: 0.5,Cell line enhanced,,AF22: 3.6;NTERA-2: 3.8;RH-30: 6.2;SCLC-21H: 8.2
12,OLIG1,"BHLHB6, bHLHe21",ENSG00000184221,Oligodendrocyte transcription factor 1,21,33070144-33072420,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,104,cerebral cortex: 142.6,kidney: 1.3,Cell line enhanced,,NB-4: 24.7;RPMI-8226: 14.1;THP-1: 17.1;U-937: 22.7
13,CACNG7,,ENSG00000105605,Calcium voltage-gated channel auxiliary subunit gamma 7,19,53909335-53943941,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,101,cerebral cortex: 63.7,adrenal gland: 0.6,Cell line enhanced,,AF22: 52.2;HMC-1: 36.0;NTERA-2: 14.0;SH-SY5Y: 34.2
14,NCAN,CSPG3,ENSG00000130287,Neurocan,19,19211973-19252233,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036814,Enhanced,,Uncertain,Vesicles<br>Centrosome,,Tissue enriched,Tissue enriched,101,cerebral cortex: 183.5,testis: 1.8,Cell line enhanced,,AF22: 1.0;SCLC-21H: 2.7;SH-SY5Y: 1.7
15,TMEM235,,ENSG00000204278,Transmembrane protein 235,17,78231310-78240987,Predicted membrane proteins,Evidence at transcript level,HPA053939,Uncertain,,,,,Tissue enriched,Tissue enriched,100,cerebral cortex: 15.6,"placenta,testis: 0.1",Not detected,,
16,SLITRK1,"KIAA1910, LRRC12",ENSG00000178235,SLIT and NTRK like family member 1,13,83877205-83882393,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA012414,Enhanced,,,,,Tissue enriched,Tissue enriched,81,cerebral cortex: 23.8,"adrenal gland,cervix, uterine,pancreas,seminal vesicle: 0.2",Cell line enhanced,,A-431: 2.6;AF22: 1.1
17,SNCB,,ENSG00000074317,Synuclein beta,5,176620084-176630556,Predicted intracellular proteins,Evidence at protein level,"CAB002681, HPA035876",Enhanced,Supported,,,,Tissue enriched,Tissue enriched,71,cerebral cortex: 329.2,adrenal gland: 4.6,Cell line enriched,15.0,SCLC-21H: 68.9
18,POU3F2,"BRN2, OCT7, OTF7, POUF3",ENSG00000184486,POU class 3 homeobox 2,6,98834592-98839470,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA047081, HPA056261",,Approved,Supported,Nucleus,,Tissue enriched,Tissue enriched,70,cerebral cortex: 20.4,testis: 0.2,Cell line enhanced,,AF22: 123.9;U-251 MG: 32.8;WM-115: 33.3
19,TTC9B,FLJ30373,ENSG00000174521,Tetratricopeptide repeat domain 9B,19,40216058-40218399,Predicted secreted proteins,Evidence at protein level,HPA042496,Uncertain,,,,,Tissue enriched,Tissue enriched,67,cerebral cortex: 57.5,adrenal gland: 0.8,Cell line enriched,21.0,SCLC-21H: 31.6
20,GPR37L1,ETBR-LP-2,ENSG00000170075,G protein-coupled receptor 37 like 1,1,202122858-202133592,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA064454,Enhanced,,,,,Tissue enriched,Tissue enriched,65,cerebral cortex: 34.1,seminal vesicle: 0.5,Cell line enhanced,,HaCaT: 1.1;MCF7: 1.1;T-47d: 3.6
21,SLC17A6,"DNPI, VGLUT2",ENSG00000091664,Solute carrier family 17 member 6,11,22338097-22379503,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB037130, HPA039226, CAB078204",Enhanced,Supported,,,,Not detected,Tissue enriched,65,cerebral cortex: 6.5,all non-specific tissues: 0.0,Cell line enriched,263.0,SCLC-21H: 35.7
22,CSPG5,NGC,ENSG00000114646,Chondroitin sulfate proteoglycan 5,3,47562239-47580792,Predicted membrane proteins,Evidence at protein level,"HPA049529, HPA067818, HPA071779",Enhanced,,Approved,Nucleoplasm<br>Mitochondria,Ovarian cancer:2.14e-4 (favourable),Tissue enriched,Tissue enriched,56,cerebral cortex: 156.7,testis: 2.8,Cell line enhanced,,AF22: 32.2
23,CAMKV,"MGC8407, VACAMKL",ENSG00000164076,CaM kinase like vesicle associated,3,49857988-49870222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007656, CAB034931",Enhanced,,Approved,Nucleoplasm<br>Cytokinetic bridge,,Group enriched,Tissue enriched,55,cerebral cortex: 86.2,testis: 1.5,Cell line enhanced,,AF22: 6.4;HAP1: 8.9;NTERA-2: 30.7;SCLC-21H: 12.2;SH-SY5Y: 7.1
24,PMP2,"FABP8, M-FABP, MP2",ENSG00000147588,Peripheral myelin protein 2,8,81440326-81447523,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,55,cerebral cortex: 288.6,seminal vesicle: 5.2,Cell line enhanced,,WM-115: 1.3
25,AMER2,"FAM123A, FLJ25477",ENSG00000165566,APC membrane recruitment protein 2,13,25161684-25172288,Predicted intracellular proteins,Evidence at protein level,HPA039458,Enhanced,,,,,Tissue enriched,Tissue enriched,53,cerebral cortex: 72.4,"fallopian tube,testis: 1.3",Group enriched,5.0,AF22: 3.6;SCLC-21H: 3.5;U-266/70: 5.2
26,SEZ6,,ENSG00000063015,Seizure related 6 homolog,17,28954901-29006440,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011777,Enhanced,,Uncertain,Intermediate filaments,,Tissue enriched,Tissue enriched,53,cerebral cortex: 54.3,duodenum: 1.0,Cell line enriched,6.0,SCLC-21H: 69.9
27,DLL3,SCDO1,ENSG00000090932,Delta like canonical Notch ligand 3,19,39498895-39508481,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA056533,,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:2.94e-4 (unfavourable),Group enriched,Tissue enriched,49,cerebral cortex: 51.3,testis: 1.0,Group enriched,6.0,SCLC-21H: 16.1;SH-SY5Y: 14.9;SK-MEL-30: 62.1
28,HAPLN2,BRAL1,ENSG00000132702,Hyaluronan and proteoglycan link protein 2,1,156619294-156625725,Predicted secreted proteins,Evidence at protein level,HPA045765,Enhanced,,,,,Tissue enriched,Tissue enriched,47,cerebral cortex: 42.1,duodenum: 0.8,Not detected,,
29,HPCA,,ENSG00000121905,Hippocalcin,1,32885994-32898441,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012340, HPA043245",Supported,,,,,Tissue enriched,Tissue enriched,47,cerebral cortex: 153.0,testis: 3.2,Cell line enriched,8.0,SCLC-21H: 5.3
30,LRTM2,,ENSG00000166159,Leucine rich repeats and transmembrane domains 2,12,1820267-1836752,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA055094,Uncertain,,,,,Not detected,Tissue enriched,47,cerebral cortex: 8.3,testis: 0.1,Group enriched,12.0,HEL: 7.7;SCLC-21H: 5.2
31,GABRA1,EJM5,ENSG00000022355,Gamma-aminobutyric acid type A receptor alpha1 subunit,5,161847063-161899981,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB022502, HPA055746",Enhanced,,,,,Tissue enriched,Tissue enriched,46,cerebral cortex: 85.0,adrenal gland: 1.8,Not detected,,
32,NR2E1,"TLL, TLX, XTLL",ENSG00000112333,Nuclear receptor subfamily 2 group E member 1,6,108166058-108188809,"Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA036954, HPA055642",Enhanced,,Approved,Nuclear bodies,,Tissue enriched,Tissue enriched,46,cerebral cortex: 11.4,adrenal gland: 0.2,Cell line enhanced,,BEWO: 2.9;U-251 MG: 3.3
33,ELAVL3,"DKFZp547J036, HUC, HUCL, MGC20653, PLE21",ENSG00000196361,ELAV like RNA binding protein 3,19,11451326-11481046,Predicted intracellular proteins,Evidence at protein level,CAB013066,Enhanced,,,,,Tissue enriched,Tissue enriched,45,cerebral cortex: 72.8,adrenal gland: 1.6,Group enriched,10.0,SCLC-21H: 95.2;SH-SY5Y: 49.4
34,NKAIN2,"FAM77B, TCBA1",ENSG00000188580,Sodium/potassium transporting ATPase interacting 2,6,123804141-124825657,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA045860,,,Approved,Cytosol,,Mixed,Tissue enriched,44,cerebral cortex: 46.1,"adipose tissue,skeletal muscle: 1.0",Cell line enhanced,,HEK93: 4.5;HEL: 5.8;Karpas-707: 7.5
35,GABRA5,,ENSG00000186297,Gamma-aminobutyric acid type A receptor alpha5 subunit,15,26866363-26949207,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA077031, CAB079022",,Supported,Supported,Plasma membrane,,Mixed,Tissue enriched,43,cerebral cortex: 81.6,esophagus: 1.8,Group enriched,10.0,A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
36,GRM3,"GPRC1C, mGlu3, MGLUR3",ENSG00000198822,Glutamate metabotropic receptor 3,7,86643914-86864884,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,43,cerebral cortex: 62.3,testis: 1.4,Cell line enriched,8.0,AF22: 35.5
37,PCDHGC5,PCDH-GAMMA-C5,ENSG00000240764,"Protocadherin gamma subfamily C, 5",5,141489121-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA051540",Uncertain,,Approved,Nucleus<br>Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,,Group enriched,Tissue enriched,43,cerebral cortex: 50.6,smooth muscle: 1.1,Cell line enhanced,,U-138 MG: 14.5;U-251 MG: 5.4;U-87 MG: 8.8
38,MEPE,,ENSG00000152595,Matrix extracellular phosphoglycoprotein,4,87821411-87846817,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038003, HPA038004",Uncertain,,,,,Not detected,Tissue enriched,41,cerebral cortex: 4.0,all non-specific tissues: 0.0,Not detected,,
39,GAP43,"B-50, PP46",ENSG00000172020,Growth associated protein 43,3,115623324-115721490,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB004417, HPA013392, HPA015600",Enhanced,,Enhanced,Plasma membrane,,Tissue enriched,Tissue enriched,38,cerebral cortex: 345.9,appendix: 9.1,Group enriched,6.0,AF22: 34.3;NTERA-2: 74.0;SCLC-21H: 55.5;SH-SY5Y: 37.6;U-87 MG: 16.1
40,TNR,,ENSG00000116147,Tenascin R,1,175315194-175743770,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB022343, HPA027134, HPA027150, HPA029859",Enhanced,,,,,Tissue enriched,Tissue enriched,38,cerebral cortex: 70.6,adrenal gland: 1.8,Cell line enhanced,,SH-SY5Y: 1.9;U-937: 1.1
41,GPM6A,GPM6,ENSG00000150625,Glycoprotein M6A,4,175632934-176002664,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017338,Supported,,,,,Tissue enriched,Tissue enriched,36,cerebral cortex: 1104.1,lung: 30.7,Group enriched,9.0,AF22: 49.3;Daudi: 30.7;HAP1: 18.0;U-251 MG: 42.1
42,FXYD7,,ENSG00000221946,FXYD domain containing ion transport regulator 7,19,35143250-35154301,Predicted membrane proteins,Evidence at protein level,HPA026916,Approved,,,,,Tissue enhanced,Tissue enriched,35,cerebral cortex: 105.8,lymph node: 3.0,Cell line enhanced,,HAP1: 1.8;HMC-1: 4.5;WM-115: 3.1
43,SLC32A1,"bA122O1.1, VGAT, VIAAT",ENSG00000101438,Solute carrier family 32 member 1,20,38724462-38729372,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB037156, HPA058859, HPA059985",Enhanced,Supported,,,,Tissue enhanced,Tissue enriched,35,cerebral cortex: 15.9,testis: 0.4,Cell line enhanced,,MOLT-4: 1.1
44,SULT4A1,"hBR-STL-1, SULTX3",ENSG00000130540,Sulfotransferase family 4A member 1,22,43824509-43862503,Predicted intracellular proteins,Evidence at protein level,HPA003129,Enhanced,,,,,Tissue enhanced,Tissue enriched,35,cerebral cortex: 143.6,adrenal gland: 4.0,Not detected,,
45,CACNG8,,ENSG00000142408,Calcium voltage-gated channel auxiliary subunit gamma 8,19,53963040-53990215,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA041351,Enhanced,,,,,Tissue enriched,Tissue enriched,34,cerebral cortex: 23.7,testis: 0.6,Cell line enhanced,,AF22: 7.2;HMC-1: 21.1;TIME: 12.3
46,CASKIN1,"ANKS5A, KIAA1306",ENSG00000167971,CASK interacting protein 1,16,2177180-2196525,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA055990, CAB079050",Enhanced,Supported,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enriched,33,cerebral cortex: 20.3,testis: 0.6,Cell line enhanced,,HDLM-2: 13.8;SCLC-21H: 7.7
47,KCNF1,"IK8, KCNF, kH1, Kv5.1",ENSG00000162975,Potassium voltage-gated channel modifier subfamily F member 1,2,10911937-10914225,"Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA014738, HPA062278",Enhanced,,Approved,Golgi apparatus,,Tissue enriched,Tissue enriched,32,cerebral cortex: 37.5,endometrium: 1.1,Cell line enhanced,,A549: 12.9;MCF7: 3.9;T-47d: 5.7
48,KCNV1,Kv8.1,ENSG00000164794,Potassium voltage-gated channel modifier subfamily V member 1,8,109963645-109975847,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,32,cerebral cortex: 21.8,"epididymis,skin,thyroid gland: 0.6",Not detected,,
49,PACSIN1,SDPI,ENSG00000124507,Protein kinase C and casein kinase substrate in neurons 1,6,34466061-34535231,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009929, HPA028852, HPA055491",Enhanced,,Approved,Nucleus<br>Vesicles,,Mixed,Tissue enriched,32,cerebral cortex: 133.6,lymph node: 4.1,Cell line enhanced,,MCF7: 9.2;RPMI-8226: 9.7;T-47d: 20.2;U-266/84: 11.7
50,SNAP25,"bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25",ENSG00000132639,Synaptosome associated protein 25,20,10218830-10307418,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000360, HPA001830",Enhanced,Supported,,,,Group enriched,Tissue enriched,31,cerebral cortex: 1759.0,adrenal gland: 57.2,Cell line enhanced,,SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7
51,VWC2L,,ENSG00000174453,Von Willebrand factor C domain containing protein 2-like,2,214411065-214578959,Predicted secreted proteins,Evidence at protein level,"HPA044815, HPA059414",Uncertain,,,,,Not detected,Tissue enriched,31,cerebral cortex: 3.1,all non-specific tissues: 0.0,Not detected,,
52,FEZF2,"FEZL, FKSG36, FLJ10142, TOF, Zfp312, ZNF312",ENSG00000153266,FEZ family zinc finger 2,3,62369681-62374324,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enriched,30,cerebral cortex: 11.7,colon: 0.3,Cell line enhanced,,AF22: 1.4;NTERA-2: 1.0
53,HS3ST2,3OST2,ENSG00000122254,Heparan sulfate-glucosamine 3-sulfotransferase 2,16,22814177-22916338,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017736,Approved,,,,"Renal cancer:1.35e-4 (favourable), Glioma:2.22e-4 (unfavourable)",Mixed,Tissue enriched,30,cerebral cortex: 35.7,lung: 1.1,Group enriched,7.0,HaCaT: 8.5;SH-SY5Y: 17.7
54,PLP1,"GPM6C, PLP, SPG2",ENSG00000123560,Proteolipid protein 1,X,103773718-103792619,"Cancer-related genes, Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA004128,Enhanced,,,,,Group enriched,Tissue enriched,30,cerebral cortex: 3216.6,parathyroid gland: 107.9,Group enriched,6.0,NTERA-2: 37.4;SK-MEL-30: 184.2;WM-115: 137.4
55,SLC1A2,"EAAT2, GLT-1",ENSG00000110436,Solute carrier family 1 member 2,11,35251206-35420063,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002574, HPA009172",Enhanced,,,,,Tissue enriched,Tissue enriched,30,cerebral cortex: 365.8,liver: 12.2,Cell line enhanced,,fHDF/TERT166: 1.5;NTERA-2: 2.4;SCLC-21H: 1.5
56,TBR1,,ENSG00000136535,"T-box, brain 1",2,161416094-161425870,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA051256, HPA078644, HPA078657",Enhanced,Approved,,,,Not detected,Tissue enriched,30,cerebral cortex: 30.6,testis: 1.0,Not detected,,
57,MBP,,ENSG00000197971,Myelin basic protein,18,76978827-77133683,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002300, HPA049222, HPA064368",Enhanced,Supported,Approved,Plasma membrane,Renal cancer:4.48e-12 (favourable),Group enriched,Tissue enriched,29,cerebral cortex: 2930.7,parathyroid gland: 99.8,Cell line enhanced,,HL-60: 79.4;SK-MEL-30: 158.4
58,PSD2,"DKFZp761B0514, EFA6C",ENSG00000146005,Pleckstrin and Sec7 domain containing 2,5,139795821-139844466,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,29,cerebral cortex: 58.5,epididymis: 2.0,Cell line enhanced,,SH-SY5Y: 1.0
59,SOX8,,ENSG00000005513,SRY-box 8,16,981808-986979,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA041640, HPA058665",Enhanced,,Supported,Nucleus,,Tissue enriched,Tissue enriched,29,cerebral cortex: 109.9,salivary gland: 3.8,Cell line enriched,5.0,RH-30: 112.8
60,SYN2,"SYNII, SYNIIa, SYNIIb",ENSG00000157152,Synapsin II,3,12004402-12191400,Predicted intracellular proteins,Evidence at protein level,"HPA037012, CAB079005",,Supported,Approved,Nucleoplasm,,Tissue enhanced,Tissue enriched,29,cerebral cortex: 200.0,testis: 6.8,Cell line enhanced,,HMC-1: 4.4;NTERA-2: 4.3;SCLC-21H: 4.0;SH-SY5Y: 14.4
61,C2orf80,"GONDA1, LOC389073",ENSG00000188674,Chromosome 2 open reading frame 80,2,208165343-208190073,Predicted intracellular proteins,Evidence at transcript level,HPA042639,,,Approved,Golgi apparatus,,Tissue enriched,Tissue enriched,28,cerebral cortex: 37.5,testis: 1.3,Cell line enhanced,,NTERA-2: 1.7
62,CACNG3,,ENSG00000006116,Calcium voltage-gated channel auxiliary subunit gamma 3,16,24255553-24362801,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA059010,Approved,,,,,Tissue enriched,Tissue enriched,28,cerebral cortex: 42.5,adrenal gland: 1.5,Not detected,,
63,KIF5A,"D12S1889, MY050, NKHC, SPG10",ENSG00000155980,Kinesin family member 5A,12,57549998-57586632,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA004469, HPA073448",Enhanced,Approved,Approved,Nucleoplasm<br>Mitotic spindle<br>Cytosol,Pancreatic cancer:5.23e-4 (favourable),Tissue enriched,Tissue enriched,28,cerebral cortex: 325.7,adrenal gland: 11.4,Cell line enhanced,,HDLM-2: 28.1;NTERA-2: 15.0;SCLC-21H: 36.2
64,NPTX1,,ENSG00000171246,Neuronal pentraxin 1,17,80467148-80477843,Predicted secreted proteins,Evidence at protein level,HPA077062,Enhanced,,,,,Tissue enhanced,Tissue enriched,28,cerebral cortex: 122.5,adrenal gland: 4.3,Cell line enhanced,,HAP1: 33.7;SiHa: 44.5;U-138 MG: 85.8;WM-115: 120.6
65,SLC39A12,FLJ30499,ENSG00000148482,Solute carrier family 39 member 12,10,17951839-18043292,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,28,cerebral cortex: 25.3,breast: 0.8,Not detected,,
66,TRIM67,TNL,ENSG00000119283,Tripartite motif containing 67,1,231162112-231221556,Predicted intracellular proteins,Evidence at transcript level,HPA034776,Uncertain,,,,,Not detected,Tissue enriched,28,cerebral cortex: 10.3,"adrenal gland,testis: 0.3",Cell line enhanced,,SCLC-21H: 2.8
67,ERMN,"ERMIN, JN, KIAA1189",ENSG00000136541,Ermin,2,157318625-157327713,Predicted intracellular proteins,Evidence at protein level,"HPA038295, HPA038296",Enhanced,,,,Endometrial cancer:6.93e-6 (favourable),Group enriched,Tissue enriched,27,cerebral cortex: 227.8,bone marrow: 8.3,Cell line enriched,8.0,HAP1: 20.7
68,SYNPR,"MGC26651, SPO",ENSG00000163630,Synaptoporin,3,63228315-63616921,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA051368, HPA061671",Enhanced,,,,,Tissue enhanced,Tissue enriched,27,cerebral cortex: 78.2,heart muscle: 2.9,Cell line enhanced,,SCLC-21H: 1.2
69,TTYH1,,ENSG00000167614,Tweety family member 1,19,54415219-54436900,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA023617, HPA050655",Approved,,,,Breast cancer:3.64e-4 (favourable),Tissue enriched,Tissue enriched,27,cerebral cortex: 57.7,"fallopian tube,testis: 2.1",Group enriched,6.0,AF22: 5.8;AN3-CA: 17.4;U-2 OS: 7.0
70,SCN2A,"HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2",ENSG00000136531,Sodium voltage-gated channel alpha subunit 2,2,165194993-165392310,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,CAB022567,Enhanced,,,,,Tissue enhanced,Tissue enriched,26,cerebral cortex: 56.6,kidney: 2.1,Cell line enhanced,,U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2
71,SYN1,,ENSG00000008056,Synapsin I,X,47571898-47619943,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000397, CAB021929",Enhanced,,,,,Tissue enhanced,Tissue enriched,26,cerebral cortex: 378.9,adrenal gland: 14.5,Cell line enhanced,,NTERA-2: 17.4;SCLC-21H: 35.6;SH-SY5Y: 8.3
72,NTSR2,NTR2,ENSG00000169006,Neurotensin receptor 2,2,11658178-11670164,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,25,cerebral cortex: 25.0,ovary: 0.9,Not detected,,
73,STMN4,RB3,ENSG00000015592,Stathmin 4,8,27235323-27258420,Predicted intracellular proteins,Evidence at protein level,HPA027765,,,Uncertain,Golgi apparatus<br>Vesicles,,Tissue enriched,Tissue enriched,25,cerebral cortex: 338.4,adrenal gland: 13.3,Cell line enriched,29.0,SCLC-21H: 102.2
74,BCAN,"BEHAB, CSPG7, MGC13038",ENSG00000132692,Brevican,1,156641390-156659532,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA007865, CAB025862",Enhanced,Supported,,,,Group enriched,Tissue enriched,24,cerebral cortex: 428.3,epididymis: 18.0,Cell line enhanced,,HDLM-2: 67.3;K-562: 92.6;U-266/84: 84.7
75,C1QL3,"C1ql, C1QTNF13, CTRP13, K100",ENSG00000165985,Complement C1q like 3,10,16513743-16522005,Predicted secreted proteins,Evidence at protein level,,,,,,Renal cancer:6.29e-5 (favourable),Mixed,Tissue enriched,24,cerebral cortex: 43.3,duodenum: 1.8,Group enriched,10.0,HDLM-2: 29.9;SCLC-21H: 22.4
76,CORT,MGC32686,ENSG00000241563,Cortistatin,1,10449719-10451902,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enriched,24,cerebral cortex: 24.8,placenta: 1.0,Mixed,,
77,SHANK1,"SPANK-1, SSTRIP, synamon",ENSG00000161681,SH3 and multiple ankyrin repeat domains 1,19,50661827-50719450,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA032129, HPA032130",Uncertain,,Supported,Plasma membrane,,Tissue enhanced,Tissue enriched,24,cerebral cortex: 35.8,adrenal gland: 1.5,Cell line enhanced,,REH: 4.6;U-138 MG: 2.6;U-2 OS: 7.1
78,TMEM151A,"MGC33486, TMEM151",ENSG00000179292,Transmembrane protein 151A,11,66291870-66296664,Predicted membrane proteins,Evidence at transcript level,HPA041035,Uncertain,,Approved,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enriched,24,cerebral cortex: 45.2,adrenal gland: 1.8,Group enriched,7.0,SCLC-21H: 17.8;SH-SY5Y: 3.7
79,FBXL16,"C16orf22, Fbl16, MGC33974",ENSG00000127585,F-box and leucine rich repeat protein 16,16,692498-705829,Predicted intracellular proteins,Evidence at protein level,"HPA039504, HPA056354",Enhanced,,,,"Endometrial cancer:6.24e-5 (unfavourable), Pancreatic cancer:7.34e-5 (favourable), Renal cancer:1.87e-4 (favourable)",Expressed in all,Tissue enriched,23,cerebral cortex: 186.4,testis: 8.0,Cell line enhanced,,AN3-CA: 16.9;SCLC-21H: 35.4;SH-SY5Y: 23.8
80,GRIN2B,"GluN2B, NMDAR2B",ENSG00000273079,Glutamate ionotropic receptor NMDA type subunit 2B,12,13437942-13981957,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA069762,Approved,,,,,Not detected,Tissue enriched,23,cerebral cortex: 13.1,"adipose tissue,testis: 0.5",Cell line enhanced,,AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
81,MOBP,,ENSG00000168314,Myelin-associated oligodendrocyte basic protein,3,39467198-39529479,Predicted intracellular proteins,Evidence at protein level,HPA035152,Supported,,,,,Tissue enriched,Tissue enriched,23,cerebral cortex: 175.9,parathyroid gland: 7.5,Cell line enriched,56.0,HAP1: 19.1
82,SV2B,"HsT19680, KIAA0735",ENSG00000185518,Synaptic vesicle glycoprotein 2B,15,91099950-91301309,Predicted membrane proteins,Evidence at protein level,HPA046247,Approved,,,,,Mixed,Tissue enriched,23,cerebral cortex: 47.9,adipose tissue: 2.1,Group enriched,6.0,RPMI-8226: 1.4;SCLC-21H: 4.6
83,JPH3,"CAGL237, HDL2, JP-3, JP3, TNRC22",ENSG00000154118,Junctophilin 3,16,87601835-87698156,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA076304,,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enriched,22,cerebral cortex: 43.3,adrenal gland: 2.0,Cell line enhanced,,MCF7: 5.8;NTERA-2: 6.6;SH-SY5Y: 8.9;SiHa: 5.9;U-2 OS: 27.3
84,SLC4A10,"NBCn2, NCBE",ENSG00000144290,Solute carrier family 4 member 10,2,161424332-161985282,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA034755,Supported,,,,,Tissue enhanced,Tissue enriched,22,cerebral cortex: 57.5,adrenal gland: 2.6,Cell line enriched,10.0,Karpas-707: 6.1
85,STX1B,"STX1B1, STX1B2",ENSG00000099365,Syntaxin 1B,16,30989256-31010661,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA069176, CAB079008",Supported,Supported,,,,Tissue enriched,Tissue enriched,22,cerebral cortex: 108.6,testis: 4.8,Cell line enhanced,,hTEC/SVTERT24-B: 11.1
86,VGF,"SCG7, SgVII",ENSG00000128564,VGF nerve growth factor inducible,7,101162509-101165593,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA055177, HPA072505",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Endometrial cancer:4.25e-4 (unfavourable), Glioma:4.43e-4 (unfavourable)",Tissue enriched,Tissue enriched,22,cerebral cortex: 46.1,adipose tissue: 2.0,Group enriched,11.0,SH-SY5Y: 182.3;SK-MEL-30: 372.7;U-2 OS: 87.3;WM-115: 139.3
87,APC2,APCL,ENSG00000115266,"APC2, WNT signaling pathway regulator",19,1446302-1473244,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA078002,,,Supported,Cytokinetic bridge<br>Midbody<br>Cytosol,,Tissue enriched,Tissue enriched,21,cerebral cortex: 70.5,adrenal gland: 3.3,Group enriched,10.0,AF22: 7.7;SCLC-21H: 11.0;SH-SY5Y: 33.6
88,CNTNAP4,"CASPR4, KIAA1763",ENSG00000152910,Contactin associated protein like 4,16,76277278-76559238,Predicted membrane proteins,Evidence at protein level,"HPA031859, HPA057342",Enhanced,,,,,Tissue enriched,Tissue enriched,21,cerebral cortex: 35.9,testis: 1.6,Group enriched,6.0,Daudi: 7.9;HSkMC: 3.0;Karpas-707: 2.6;RPMI-8226: 4.9
89,CYP46A1,CYP46,ENSG00000036530,Cytochrome P450 family 46 subfamily A member 1,14,99684304-99727301,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040702,Uncertain,,,,,Tissue enriched,Tissue enriched,21,cerebral cortex: 64.1,heart muscle: 3.0,Group enriched,5.0,AF22: 2.4;U-937: 5.4
90,C11orf87,"LOC399947, LOH11CR1A, NEURIM1",ENSG00000185742,Chromosome 11 open reading frame 87,11,109422120-109429114,Predicted membrane proteins,Evidence at protein level,HPA034656,Approved,,,,,Tissue enhanced,Tissue enriched,20,cerebral cortex: 30.8,endometrium: 1.5,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 2.7;fHDF/TERT166: 9.0;SCLC-21H: 3.4
91,CMTM5,"CKLFSF5, FLJ37521",ENSG00000166091,CKLF like MARVEL transmembrane domain containing 5,14,23376808-23379772,Predicted membrane proteins,Evidence at protein level,HPA052338,Enhanced,,Approved,Golgi apparatus<br>Vesicles,,Group enriched,Tissue enriched,20,cerebral cortex: 81.3,seminal vesicle: 4.1,Cell line enriched,6.0,HEL: 73.9
92,FAM181B,"LOC220382, MGC33846",ENSG00000182103,Family with sequence similarity 181 member B,11,82729941-82733864,Predicted intracellular proteins,Evidence at transcript level,HPA066861,Approved,,Approved,Nuclear membrane<br>Mitochondria,Endometrial cancer:8.07e-4 (favourable),Tissue enriched,Tissue enriched,20,cerebral cortex: 17.5,"adrenal gland,fallopian tube: 0.8",Cell line enhanced,,RT4: 1.9;SH-SY5Y: 1.3;U-2 OS: 1.3
93,GDAP1L1,,ENSG00000124194,Ganglioside induced differentiation associated protein 1 like 1,20,44247099-44280917,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA054182, HPA063265",Approved,,Approved,Endoplasmic reticulum,,Tissue enriched,Tissue enriched,20,cerebral cortex: 55.6,adrenal gland: 2.8,Group enriched,6.0,NTERA-2: 11.9;SCLC-21H: 34.5;SH-SY5Y: 15.2
94,VSTM2B,,ENSG00000187135,V-set and transmembrane domain containing 2B,19,29526499-29564479,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enriched,20,cerebral cortex: 42.3,"cervix, uterine: 2.1",Group enriched,7.0,SCLC-21H: 1.3;SK-MEL-30: 6.2
95,ACTL6B,"ACTL6, BAF53B",ENSG00000077080,Actin like 6B,7,100643097-100656461,Predicted intracellular proteins,Evidence at protein level,HPA045126,Uncertain,,Approved,Nucleoli,,Group enriched,Tissue enriched,19,cerebral cortex: 45.6,adrenal gland: 2.4,Group enriched,92.0,SCLC-21H: 33.1;SH-SY5Y: 30.4
96,BTBD17,"BTBD17A, LGALS3BPL, TANGO10A",ENSG00000204347,BTB domain containing 17,17,74356416-74361946,Predicted secreted proteins,Evidence at protein level,HPA025022,Approved,,,,,Group enriched,Tissue enriched,19,cerebral cortex: 12.9,adrenal gland: 0.6,Group enriched,24.0,AF22: 2.7;NTERA-2: 3.6;SCLC-21H: 12.8
97,CTNND2,"GT24, NPRAP",ENSG00000169862,Catenin delta 2,5,10971840-11904043,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA015077, CAB037339",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cell Junctions,,Tissue enriched,Tissue enriched,18,cerebral cortex: 103.2,spleen: 5.6,Cell line enhanced,,AF22: 19.5;MCF7: 7.1;SK-BR-3: 4.4;U-266/84: 12.6
98,GABBR2,"GABABR2, GPR51, GPRC3B, HG20",ENSG00000136928,Gamma-aminobutyric acid type B receptor subunit 2,9,98288082-98709197,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA013820, HPA031684, CAB079065",Enhanced,Approved,,,,Group enriched,Tissue enriched,18,cerebral cortex: 77.9,adrenal gland: 4.3,Cell line enhanced,,BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3
99,C1QL2,"C1QTNF10, CTRP10",ENSG00000144119,Complement C1q like 2,2,119156243-119158889,Predicted secreted proteins,Evidence at protein level,HPA057934,Uncertain,,,,,Mixed,Tissue enriched,17,cerebral cortex: 2.5,"lymph node,testis: 0.1",Cell line enhanced,,SCLC-21H: 2.8
100,GABRG1,,ENSG00000163285,Gamma-aminobutyric acid type A receptor gamma1 subunit,4,46035769-46124081,"FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,HPA035622,Approved,,,,,Tissue enriched,Tissue enriched,17,cerebral cortex: 26.0,ovary: 1.5,Cell line enhanced,,U-266/70: 1.1
101,GAD2,GAD65,ENSG00000136750,Glutamate decarboxylase 2,10,26216307-26304558,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044637, CAB078177",Enhanced,,,,,Group enriched,Tissue enriched,17,cerebral cortex: 22.9,pancreas: 1.3,Group enriched,13.0,MOLT-4: 2.4;SCLC-21H: 7.4
102,GNG3,,ENSG00000162188,G protein subunit gamma 3,11,62707658-62709201,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,17,cerebral cortex: 315.2,adrenal gland: 19.0,Group enriched,7.0,Karpas-707: 104.6;SCLC-21H: 335.7
103,GPM6B,"M6B, MGC17150, MGC54284",ENSG00000046653,Glycoprotein M6B,X,13771031-13938638,Predicted membrane proteins,Evidence at protein level,HPA002913,Approved,,,,Ovarian cancer:2.67e-4 (favourable),Group enriched,Tissue enriched,17,cerebral cortex: 835.8,seminal vesicle: 48.6,Cell line enhanced,,AF22: 147.7;AN3-CA: 138.3;HSkMC: 79.6;SK-MEL-30: 117.9
104,GPR158,KIAA1136,ENSG00000151025,G protein-coupled receptor 158,10,25175062-25602226,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA013185,Uncertain,,Approved,Cytosol,,Mixed,Tissue enriched,17,cerebral cortex: 17.9,testis: 1.0,Cell line enhanced,,HEL: 18.7;T-47d: 5.2
105,HRH3,GPCR97,ENSG00000101180,Histamine receptor H3,20,62214970-62220267,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enriched,17,cerebral cortex: 11.1,adrenal gland: 0.6,Cell line enriched,7.0,SCLC-21H: 18.6
106,KCNK12,"K2p12.1, THIK-2, THIK2",ENSG00000184261,Potassium two pore domain channel subfamily K member 12,2,47516581-47570939,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,17,cerebral cortex: 5.3,"placenta,testis: 0.3",Group enriched,6.0,REH: 21.5;SCLC-21H: 10.5
107,MT3,GIF,ENSG00000087250,Metallothionein 3,16,56589074-56591088,Predicted intracellular proteins,Evidence at protein level,"HPA004011, CAB017779",Enhanced,,,,,Tissue enriched,Tissue enriched,17,cerebral cortex: 738.6,adrenal gland: 42.9,Group enriched,7.0,RPMI-8226: 3.1;SCLC-21H: 8.7;U-87 MG: 12.1
108,NRGN,RC3,ENSG00000154146,Neurogranin,11,124739846-124747210,Predicted intracellular proteins,Evidence at protein level,"CAB006908, HPA038171",Enhanced,,,,Renal cancer:1.52e-5 (unfavourable),Expressed in all,Tissue enriched,17,cerebral cortex: 961.5,lung: 56.2,Cell line enhanced,,HEL: 133.6;PC-3: 108.8
109,BAALC,,ENSG00000164929,"Brain and acute leukemia, cytoplasmic",8,103140710-103230305,Predicted intracellular proteins,Evidence at protein level,"HPA027132, HPA068307",Approved,,Supported,Nucleus<br>Cytosol,,Tissue enriched,Tissue enriched,16,cerebral cortex: 247.7,adrenal gland: 15.6,Cell line enhanced,,AF22: 50.6;SCLC-21H: 32.7;SH-SY5Y: 21.7;U-87 MG: 73.6
110,CEND1,"BM88, FLJ90066",ENSG00000184524,Cell cycle exit and neuronal differentiation 1,11,787104-790123,Predicted membrane proteins,Evidence at protein level,HPA042527,Enhanced,,Approved,Mitochondria,Glioma:6.10e-5 (unfavourable),Tissue enriched,Tissue enriched,16,cerebral cortex: 113.9,adrenal gland: 7.0,Cell line enhanced,,Karpas-707: 21.5;SCLC-21H: 62.8;SH-SY5Y: 21.2;U-266/70: 15.9;U-87 MG: 27.1
111,ERC2,"CAST, CAST1, ELKSL, KIAA0378, SPBC110, Spc110",ENSG00000187672,ELKS/RAB6-interacting/CAST family member 2,3,55508308-56468363,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA073739,Enhanced,,,,,Mixed,Tissue enriched,16,cerebral cortex: 24.6,seminal vesicle: 1.5,Cell line enhanced,,HAP1: 2.7;Karpas-707: 6.2;SH-SY5Y: 2.2;U-266/70: 4.6
112,GPR26,,ENSG00000154478,G protein-coupled receptor 26,10,123666355-123694607,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA062736,Enhanced,,,,,Tissue enriched,Tissue enriched,16,cerebral cortex: 4.3,testis: 0.2,Cell line enriched,15.0,SCLC-21H: 1.4
113,GPR6,,ENSG00000146360,G protein-coupled receptor 6,6,109978256-109980718,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,16,cerebral cortex: 1.5,all non-specific tissues: 0.0,Cell line enriched,11.0,SCLC-21H: 1.1
114,NETO1,"BCTL1, BTCL1",ENSG00000166342,Neuropilin and tolloid like 1,18,72742314-72868146,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA064630,,,Approved,Golgi apparatus,,Tissue enhanced,Tissue enriched,16,cerebral cortex: 64.0,spleen: 4.1,Cell line enhanced,,MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0
115,SLC1A3,"EA6, EAAT1, GLAST",ENSG00000079215,Solute carrier family 1 member 3,5,36606355-36688334,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002573, HPA037467, HPA037468",Enhanced,,Approved,Nucleoli<br>Mitochondria,,Tissue enriched,Tissue enriched,16,cerebral cortex: 518.2,adipose tissue: 31.9,Cell line enhanced,,AF22: 49.5;CACO-2: 68.8;HaCaT: 55.0
116,TMEM59L,"BSMAP, C19orf4",ENSG00000105696,Transmembrane protein 59 like,19,18607430-18621039,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at transcript level,"HPA010661, HPA070701",Approved,,Approved,Nucleoplasm<br>Actin filaments,"Endometrial cancer:1.62e-4 (unfavourable), Pancreatic cancer:8.80e-4 (favourable)",Tissue enriched,Tissue enriched,16,cerebral cortex: 366.3,adrenal gland: 22.2,Cell line enhanced,,AN3-CA: 33.4;ASC diff: 29.2;EFO-21: 24.0;Hep G2: 18.4;SH-SY5Y: 22.4
117,UNC13A,"KIAA1032, Munc13-1",ENSG00000130477,Unc-13 homolog A,19,17601328-17688365,Predicted intracellular proteins,Evidence at protein level,"HPA041418, HPA077242",Uncertain,,Uncertain,Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol,,Tissue enhanced,Tissue enriched,16,cerebral cortex: 53.5,adrenal gland: 3.4,Group enriched,7.0,HMC-1: 14.3;NTERA-2: 23.7;SCLC-21H: 45.8;SH-SY5Y: 9.8
118,CHRNB2,,ENSG00000160716,Cholinergic receptor nicotinic beta 2 subunit,1,154567781-154580026,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,15,cerebral cortex: 21.2,adrenal gland: 1.4,Group enriched,7.0,SCLC-21H: 30.2;SH-SY5Y: 27.0
119,DPF1,"BAF45b, NEUD4, neuro-d4",ENSG00000011332,Double PHD fingers 1,19,38211006-38229714,Predicted intracellular proteins,Evidence at protein level,HPA049148,Enhanced,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enriched,15,cerebral cortex: 27.4,testis: 1.8,Cell line enhanced,,SCLC-21H: 26.9
120,ENC1,"ENC-1, KLHL37, NRPB, PIG10, TP53I10",ENSG00000171617,Ectodermal-neural cortex 1,5,74627406-74641424,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA078061,,,Uncertain,Plasma membrane,"Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable)",Expressed in all,Tissue enriched,15,cerebral cortex: 461.4,gallbladder: 30.8,Mixed,,
121,LY6H,NMLY6,ENSG00000176956,Lymphocyte antigen 6 family member H,8,143157914-143160711,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,15,cerebral cortex: 38.0,duodenum: 2.5,Cell line enhanced,,MOLT-4: 2.0;SCLC-21H: 1.5
122,OLFM3,NOE3,ENSG00000118733,Olfactomedin 3,1,101802574-101997030,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA050297,,,Uncertain,Vesicles,,Mixed,Tissue enriched,15,cerebral cortex: 26.7,adrenal gland: 1.8,Group enriched,11.0,AF22: 5.5;HAP1: 4.0;HEL: 3.2;SCLC-21H: 2.6;SH-SY5Y: 2.3
123,PTPN5,"PTPSTEP, STEP, STEP61",ENSG00000110786,"Protein tyrosine phosphatase, non-receptor type 5",11,18727928-18792721,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031014, HPA072091",Supported,,Approved,Endoplasmic reticulum,,Group enriched,Tissue enriched,15,cerebral cortex: 58.8,testis: 3.8,Cell line enhanced,,NTERA-2: 1.7
124,RASL10A,RRP22,ENSG00000100276,RAS like family 10 member A,22,29312933-29319679,Predicted intracellular proteins,Evidence at protein level,HPA056169,Approved,,,,,Tissue enhanced,Tissue enriched,15,cerebral cortex: 33.5,breast: 2.2,Cell line enhanced,,HEK93: 1.4;NB-4: 1.5;U-2 OS: 1.1;U-266/70: 2.0
125,SOX11,,ENSG00000176887,SRY-box 11,2,5692667-5701385,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA000536, CAB056152, CAB056153",Approved,,,,,Group enriched,Tissue enriched,15,cerebral cortex: 5.4,smooth muscle: 0.3,Group enriched,7.0,AF22: 48.1;NTERA-2: 23.8;REH: 16.5;RH-30: 18.0;SCLC-21H: 35.0;SH-SY5Y: 47.7;WM-115: 11.2
126,STX1A,"HPC-1, p35-1, STX1",ENSG00000106089,Syntaxin 1A,7,73699206-73719672,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB008372, HPA069176",Enhanced,,,,"Endometrial cancer:1.94e-5 (unfavourable), Cervical cancer:3.63e-4 (unfavourable)",Expressed in all,Tissue enriched,15,cerebral cortex: 166.6,gallbladder: 10.8,Cell line enhanced,,SCLC-21H: 164.0;U-87 MG: 90.3
127,SVOP,DKFZp761H039,ENSG00000166111,SV2 related protein,12,108907741-109021240,Predicted membrane proteins,Evidence at protein level,HPA016573,Uncertain,,,,,Group enriched,Tissue enriched,15,cerebral cortex: 32.2,adrenal gland: 2.0,Cell line enhanced,,Karpas-707: 2.0;RPMI-8226: 2.0;SCLC-21H: 1.8;SH-SY5Y: 1.4
128,ADGRB2,BAI2,ENSG00000121753,Adhesion G protein-coupled receptor B2,1,31727117-31764893,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA052612, HPA054617",,,Supported,Centrosome,"Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)",Tissue enhanced,Tissue enriched,14,cerebral cortex: 72.3,adrenal gland: 5.1,Cell line enhanced,,SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
129,C1QL1,"C1QRF, C1QTNF14, CRF",ENSG00000131094,Complement C1q like 1,17,44959693-44968071,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.31e-8 (unfavourable),Tissue enriched,Tissue enriched,14,cerebral cortex: 38.4,prostate: 2.6,Cell line enhanced,,SCLC-21H: 49.2;SH-SY5Y: 31.5;U-2 OS: 108.2;U-87 MG: 32.8
130,C8orf46,MGC33510,ENSG00000169085,Chromosome 8 open reading frame 46,8,66460003-66518524,Predicted intracellular proteins,Evidence at protein level,HPA075134,,,Approved,Nuclear speckles,,Tissue enriched,Tissue enriched,14,cerebral cortex: 65.1,seminal vesicle: 4.5,Cell line enhanced,,LHCN-M2: 1.8;SK-MEL-30: 1.9;T-47d: 2.8;WM-115: 2.9
131,CADM2,"IGSF4D, Necl-3, NECL3, SynCAM2",ENSG00000175161,Cell adhesion molecule 2,3,84958981-86074429,Predicted membrane proteins,Evidence at protein level,HPA010024,Enhanced,,,,,Tissue enriched,Tissue enriched,14,cerebral cortex: 86.2,seminal vesicle: 6.2,Cell line enhanced,,AF22: 10.8;AN3-CA: 29.1
132,DNM1,DNM,ENSG00000106976,Dynamin 1,9,128191655-128255248,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005920, HPA049910, HPA061801",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enriched,14,cerebral cortex: 364.2,"cervix, uterine: 25.6",Cell line enhanced,,A549: 114.8
133,GPR62,,ENSG00000180929,G protein-coupled receptor 62,3,51955314-51957504,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enriched,14,cerebral cortex: 8.0,ovary: 0.5,Cell line enriched,6.0,SCLC-21H: 2.2
134,KCNQ3,"EBN2, Kv7.3",ENSG00000184156,Potassium voltage-gated channel subfamily Q member 3,8,132120858-132481019,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Mixed,Tissue enriched,14,cerebral cortex: 26.7,adrenal gland: 1.9,Cell line enhanced,,hTERT-HME1: 5.1;U-2 OS: 4.5;U-87 MG: 3.5
135,KIF3C,,ENSG00000084731,Kinesin family member 3C,2,25926596-25982749,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035755,,,Approved,Nuclear membrane<br>Nuclear bodies<br>Intermediate filaments,"Endometrial cancer:1.32e-5 (unfavourable), Melanoma:1.22e-4 (favourable), Renal cancer:7.57e-4 (unfavourable)",Expressed in all,Tissue enriched,14,cerebral cortex: 129.6,adrenal gland: 9.1,Cell line enhanced,,SH-SY5Y: 57.6
136,MGAT5B,"FLJ25132, GnT-IX, GnT-VB",ENSG00000167889,"Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B",17,76868456-76950393,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011082,,,Approved,Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle,,Group enriched,Tissue enriched,14,cerebral cortex: 23.1,testis: 1.6,Cell line enhanced,,A549: 28.7;SCLC-21H: 18.6;U-138 MG: 18.3;U-2 OS: 21.0
137,NRSN1,"p24, VMP",ENSG00000152954,Neurensin 1,6,24126122-24154900,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA061006,Approved,,Approved,Nucleus<br>Vesicles,,Tissue enriched,Tissue enriched,14,cerebral cortex: 96.3,adrenal gland: 6.6,Cell line enhanced,,SCLC-21H: 14.0;SH-SY5Y: 10.0
138,SLIT1,"MEGF4, SLIL1, Slit-1, slit1, SLIT3",ENSG00000187122,Slit guidance ligand 1,10,96998038-97185920,Predicted secreted proteins,Evidence at protein level,HPA006879,,,Approved,Plasma membrane,,Group enriched,Tissue enriched,14,cerebral cortex: 60.0,thyroid gland: 4.2,Cell line enriched,11.0,MOLT-4: 64.7
139,SYT11,"DKFZp781D015, KIAA0080, MGC10881, MGC17226",ENSG00000132718,Synaptotagmin 11,1,155859509-155885199,Predicted intracellular proteins,Evidence at protein level,HPA064091,Enhanced,,,,Endometrial cancer:2.93e-5 (unfavourable),Tissue enriched,Tissue enriched,14,cerebral cortex: 402.2,endometrium: 28.4,Cell line enhanced,,Karpas-707: 130.6;SCLC-21H: 84.6;SH-SY5Y: 83.1;U-87 MG: 84.4
140,TMEM88B,,ENSG00000205116,Transmembrane protein 88B,1,1426128-1427787,Predicted membrane proteins,Evidence at protein level,HPA065743,Enhanced,,,,,Tissue enhanced,Tissue enriched,14,cerebral cortex: 11.8,testis: 0.8,Cell line enhanced,,Hep G2: 2.8;SCLC-21H: 1.9
141,VSNL1,"HLP3, HPCAL3, HUVISL1, VILIP, VILIP-1",ENSG00000163032,Visinin like 1,2,17539126-17657018,Predicted intracellular proteins,Evidence at protein level,HPA053808,,,,,Glioma:9.39e-4 (unfavourable),Mixed,Tissue enriched,14,cerebral cortex: 624.2,esophagus: 44.0,Cell line enhanced,,HaCaT: 107.2;Hep G2: 85.4
142,APLP1,APLP,ENSG00000105290,Amyloid beta precursor like protein 1,19,35867899-35879791,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028970, HPA028971",Enhanced,,,,"Urothelial cancer:2.65e-5 (unfavourable), Endometrial cancer:3.87e-4 (unfavourable)",Tissue enhanced,Tissue enriched,13,cerebral cortex: 440.4,adrenal gland: 34.5,Cell line enhanced,,AN3-CA: 137.3;SCLC-21H: 100.6;SH-SY5Y: 91.5
143,CACNG2,"MGC138502, MGC138504, stargazin",ENSG00000166862,Calcium voltage-gated channel auxiliary subunit gamma 2,22,36563921-36703558,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Tissue enriched,13,cerebral cortex: 15.3,adrenal gland: 1.2,Group enriched,11.0,SCLC-21H: 3.3;SH-SY5Y: 1.3
144,KIF1A,"ATSV, C2orf20, SPG30, UNC104",ENSG00000130294,Kinesin family member 1A,2,240713764-240820308,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA005442,,,Approved,Microtubule organizing center<br>Cytosol,Endometrial cancer:4.97e-4 (unfavourable),Tissue enhanced,Tissue enriched,13,cerebral cortex: 308.3,adrenal gland: 23.0,Cell line enhanced,,AN3-CA: 79.8;HAP1: 157.5;K-562: 125.1;SCLC-21H: 477.1
145,LINGO1,"FLJ14594, LERN1, LRRN6A",ENSG00000169783,Leucine rich repeat and Ig domain containing 1,15,77613027-77820900,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074653,Enhanced,,Approved,Plasma membrane,Renal cancer:3.23e-7 (unfavourable),Expressed in all,Tissue enriched,13,cerebral cortex: 130.8,placenta: 9.8,Cell line enhanced,,AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK93: 19.6;NTERA-2: 56.8
146,NCDN,"NCDN-1, NCDN-2",ENSG00000020129,Neurochondrin,1,35557473-35567274,Predicted intracellular proteins,Evidence at protein level,HPA023676,Enhanced,Supported,Supported,Cytosol,"Liver cancer:1.91e-5 (unfavourable), Pancreatic cancer:3.73e-4 (favourable)",Expressed in all,Tissue enriched,13,cerebral cortex: 284.4,adrenal gland: 22.7,Expressed in all,,
147,NKAIN4,"bA261N11.2, C20orf58, FAM77A",ENSG00000101198,Sodium/potassium transporting ATPase interacting 4,20,63240784-63272694,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA029876,Approved,,,,Endometrial cancer:3.14e-4 (unfavourable),Tissue enriched,Tissue enriched,13,cerebral cortex: 71.8,kidney: 5.5,Cell line enhanced,,BEWO: 23.2;MOLT-4: 33.2
148,NPTXR,,ENSG00000221890,Neuronal pentraxin receptor,22,38818452-38843982,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA001079,Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:2.85e-4 (unfavourable), Cervical cancer:3.93e-4 (favourable)",Expressed in all,Tissue enriched,13,cerebral cortex: 176.4,prostate: 13.3,Cell line enhanced,,SCLC-21H: 36.6;U-87 MG: 86.8
149,RGR,RP44,ENSG00000148604,Retinal G protein coupled receptor,10,84245053-84259960,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,13,cerebral cortex: 16.1,testis: 1.2,Not detected,,
150,SCG3,"FLJ90833, SgIII",ENSG00000104112,Secretogranin III,15,51681353-51721031,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA006880, CAB033274, HPA053715",Enhanced,Approved,Enhanced,Vesicles,,Group enriched,Tissue enriched,13,cerebral cortex: 278.4,adrenal gland: 21.9,Group enriched,8.0,NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1
151,SHISA7,,ENSG00000187902,Shisa family member 7,19,55428740-55442863,Predicted membrane proteins,Evidence at protein level,HPA058935,Uncertain,,,,,Tissue enriched,Tissue enriched,13,cerebral cortex: 18.2,testis: 1.4,Cell line enhanced,,HEL: 2.7;HMC-1: 2.7;THP-1: 1.1
152,SYT1,"P65, SVP65, SYT",ENSG00000067715,Synaptotagmin 1,12,78863993-79452008,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008394, HPA064788",Enhanced,Supported,,,,Mixed,Tissue enriched,13,cerebral cortex: 476.5,smooth muscle: 36.7,Cell line enhanced,,hTERT-HME1: 29.8;LHCN-M2: 26.5;SH-SY5Y: 32.1;WM-115: 28.3
153,ATCAY,BNIP-H,ENSG00000167654,"ATCAY, caytaxin",19,3879864-3928079,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA017755,Enhanced,,,,,Tissue enriched,Tissue enriched,12,cerebral cortex: 108.9,adrenal gland: 8.8,Cell line enhanced,,NTERA-2: 7.2;SCLC-21H: 15.5;SH-SY5Y: 9.8
154,ATP6V1G2,"ATP6G, ATP6G2, Em:AC004181.3, NG38, Vma10",ENSG00000213760,ATPase H+ transporting V1 subunit G2,6,31544462-31548427,Predicted intracellular proteins,Evidence at protein level,CAB004616,Enhanced,,,,,Tissue enriched,Tissue enriched,12,cerebral cortex: 16.7,lymph node: 1.4,Cell line enhanced,,HDLM-2: 3.0;Karpas-707: 2.5
155,ENHO,"C9orf165, UNQ470",ENSG00000168913,Energy homeostasis associated,9,34521040-34523041,Predicted secreted proteins,Evidence at transcript level,HPA042575,Approved,,,,Endometrial cancer:3.71e-4 (unfavourable),Tissue enhanced,Tissue enriched,12,cerebral cortex: 140.3,testis: 11.5,Cell line enhanced,,AN3-CA: 14.6;NTERA-2: 21.5;SCLC-21H: 12.8;SH-SY5Y: 10.9
156,GABRB1,,ENSG00000163288,Gamma-aminobutyric acid type A receptor beta1 subunit,4,46993723-47426444,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051297,Uncertain,,,,,Tissue enhanced,Tissue enriched,12,cerebral cortex: 19.7,heart muscle: 1.5,Cell line enhanced,,REH: 1.4;U-87 MG: 2.4
157,GABRB2,,ENSG00000145864,Gamma-aminobutyric acid type A receptor beta2 subunit,5,161288429-161549044,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001964, HPA067632",Enhanced,,,,,Tissue enriched,Tissue enriched,12,cerebral cortex: 62.8,epididymis: 5.2,Cell line enriched,17.0,SCLC-21H: 27.6
158,GABRD,,ENSG00000187730,Gamma-aminobutyric acid type A receptor delta subunit,1,2019298-2030758,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA044371,Enhanced,,Uncertain,Golgi apparatus<br>Vesicles,Renal cancer:4.12e-8 (unfavourable),Expressed in all,Tissue enriched,12,cerebral cortex: 34.0,testis: 2.7,Cell line enhanced,,EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
159,GABRG2,,ENSG00000113327,Gamma-aminobutyric acid type A receptor gamma2 subunit,5,162000057-162162977,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB079060,,Supported,,,,Tissue enhanced,Tissue enriched,12,cerebral cortex: 66.5,adrenal gland: 5.3,Cell line enhanced,,CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6
160,KCNK4,"K2p4.1, TRAAK",ENSG00000182450,Potassium two pore domain channel subfamily K member 4,11,64291302-64300031,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Not detected,Tissue enriched,12,cerebral cortex: 4.3,"cervix, uterine: 0.3",Not detected,,
161,MAST1,"KIAA0973, SAST",ENSG00000105613,Microtubule associated serine/threonine kinase 1,19,12833951-12874951,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028181, HPA073106",Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enriched,12,cerebral cortex: 35.2,testis: 3.0,Cell line enhanced,,AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4
162,NRXN1,"Hs.22998, KIAA0578",ENSG00000179915,Neurexin 1,2,49918505-51225575,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA071400,,,Approved,Nucleoli<br>Plasma membrane,,Tissue enriched,Tissue enriched,12,cerebral cortex: 154.0,seminal vesicle: 12.9,Cell line enriched,9.0,SCLC-21H: 42.8
163,PNMA2,"MA2, RGAG2",ENSG00000240694,Paraneoplastic Ma antigen 2,8,26504686-26514092,Predicted intracellular proteins,Evidence at protein level,HPA001936,Enhanced,,,,"Lung cancer:1.81e-4 (favourable), Stomach cancer:6.23e-4 (unfavourable)",Tissue enhanced,Tissue enriched,12,cerebral cortex: 163.4,adrenal gland: 13.5,Cell line enhanced,,AF22: 59.2;HAP1: 38.7;SH-SY5Y: 45.6
164,RAB3A,,ENSG00000105649,"RAB3A, member RAS oncogene family",19,18196784-18204074,Predicted intracellular proteins,Evidence at protein level,"HPA003160, CAB009949, CAB078998",Enhanced,Supported,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,"Renal cancer:6.14e-7 (favourable), Endometrial cancer:3.17e-4 (unfavourable)",Expressed in all,Tissue enriched,12,cerebral cortex: 250.5,adrenal gland: 20.6,Cell line enhanced,,SCLC-21H: 43.5;U-2197: 23.9
165,SLC35F1,"C6orf169, dJ230I3.1",ENSG00000196376,Solute carrier family 35 member F1,6,117907526-118317676,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019576,Enhanced,,Approved,Nucleoplasm<br>Microtubule organizing center<br>Cytosol,,Group enriched,Tissue enriched,12,cerebral cortex: 45.4,epididymis: 3.7,Group enriched,10.0,AF22: 47.2;WM-115: 80.1
166,TMEM132D,"KIAA1944, MOLT, PPP1R153",ENSG00000151952,Transmembrane protein 132D,12,129071725-129903666,Predicted membrane proteins,Evidence at protein level,HPA010739,Approved,,,,,Mixed,Tissue enriched,12,cerebral cortex: 12.3,testis: 1.0,Cell line enhanced,,AF22: 2.6;MOLT-4: 3.9;NTERA-2: 1.8
167,B3GAT1,"CD57, GlcAT-P, HNK-1, LEU7, NK-1",ENSG00000109956,"Beta-1,3-glucuronyltransferase 1",11,134378504-134411918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002500, CAB010893, HPA069468",Enhanced,,Supported,Vesicles,,Group enriched,Tissue enriched,11,cerebral cortex: 115.4,thyroid gland: 10.3,Cell line enhanced,,AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0
168,CNIH2,"CNIH-2, Cnil, MGC50896",ENSG00000174871,Cornichon family AMPA receptor auxiliary protein 2,11,66278190-66285301,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,11,cerebral cortex: 52.9,adrenal gland: 4.6,Cell line enhanced,,SCLC-21H: 74.6;SH-SY5Y: 31.1
169,CNP,,ENSG00000173786,"2',3'-cyclic nucleotide 3' phosphodiesterase",17,41966741-41977731,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002672, HPA023266, HPA023278, HPA023280, HPA023338",Enhanced,Supported,Enhanced,Nucleus<br>Cytosol,,Expressed in all,Tissue enriched,11,cerebral cortex: 614.8,prostate: 54.9,Expressed in all,,
170,CPLX1,CPX-I,ENSG00000168993,Complexin 1,4,784957-826198,Predicted intracellular proteins,Evidence at protein level,HPA071191,,,Uncertain,Vesicles,"Cervical cancer:4.20e-4 (unfavourable), Pancreatic cancer:5.05e-4 (favourable)",Expressed in all,Tissue enriched,11,cerebral cortex: 60.2,adipose tissue: 5.3,Cell line enriched,7.0,SCLC-21H: 95.0
171,DSCAM,"CHD2-42, CHD2-52",ENSG00000171587,DS cell adhesion molecule,21,40010999-40847139,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA019324,Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enriched,11,cerebral cortex: 12.4,"placenta,spleen: 1.0",Cell line enhanced,,HBEC3-KT: 2.6;MCF7: 6.2;NTERA-2: 2.2;SCLC-21H: 3.9;T-47d: 2.0
172,HPCAL4,"DKFZp761G122, HLP4",ENSG00000116983,Hippocalcin like 4,1,39678648-39691689,Predicted intracellular proteins,Evidence at protein level,HPA053808,,,Approved,Cytosol,,Group enriched,Tissue enriched,11,cerebral cortex: 145.7,adrenal gland: 13.3,Cell line enhanced,,SH-SY5Y: 9.4;SK-MEL-30: 2.2;U-266/84: 2.1
173,HTR5A,5-HT5A,ENSG00000157219,5-hydroxytryptamine receptor 5A,7,155070324-155085749,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,CAB017467,Approved,,,,,Not detected,Tissue enriched,11,cerebral cortex: 8.6,testis: 0.7,Not detected,,
174,IL1RAPL1,"IL1R8, IL1RAPL, MRX10, MRX21, MRX34, OPHN4, TIGIRR-2",ENSG00000169306,Interleukin 1 receptor accessory protein like 1,X,28587399-29956723,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,11,cerebral cortex: 5.1,"ovary,prostate,seminal vesicle: 0.4",Cell line enhanced,,WM-115: 2.5
175,KCNC2,Kv3.2,ENSG00000166006,Potassium voltage-gated channel subfamily C member 2,12,75040077-75209868,"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA019664, CAB022571",Uncertain,,Supported,Plasma membrane<br>Cytosol,,Group enriched,Tissue enriched,11,cerebral cortex: 46.4,prostate: 4.3,Not detected,,
176,KIRREL3,"KIAA1867, KIRRE, NEPH2",ENSG00000149571,Kin of IRRE like 3 (Drosophila),11,126423359-127003460,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA053324, HPA056320",Enhanced,,,,,Tissue enhanced,Tissue enriched,11,cerebral cortex: 20.4,adrenal gland: 1.9,Cell line enhanced,,BJ: 21.4;BJ hTERT+: 12.0;fHDF/TERT166: 14.2;U-138 MG: 11.2;U-251 MG: 11.6
177,LGI1,"EPITEMPIN, EPT, ETL1, IB1099",ENSG00000108231,Leucine rich glioma inactivated 1,10,93757809-93806272,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,11,cerebral cortex: 45.4,esophagus: 4.2,Group enriched,5.0,AF22: 9.4;NTERA-2: 6.4
178,LHX2,"hLhx2, LH-2",ENSG00000106689,LIM homeobox 2,9,124001670-124033301,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA000838,,Supported,Approved,Nucleoplasm,Cervical cancer:9.52e-4 (favourable),Group enriched,Tissue enriched,11,cerebral cortex: 56.3,placenta: 5.1,Cell line enhanced,,AN3-CA: 22.0;HAP1: 24.5;NTERA-2: 29.4
179,MAP2,"MAP2A, MAP2B, MAP2C",ENSG00000078018,Microtubule associated protein 2,2,209424058-209734118,"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001984, HPA008273, HPA012828",Enhanced,Supported,Supported,Nucleoli<br>Cytosol,Endometrial cancer:1.98e-6 (unfavourable),Tissue enhanced,Tissue enriched,11,cerebral cortex: 296.5,thyroid gland: 27.9,Cell line enhanced,,AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2
180,MYT1L,"KIAA1106, NZF1, ZC2H2C2, ZC2HC4B",ENSG00000186487,Myelin transcription factor 1 like,2,1789113-2331260,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060245,,,Approved,Vesicles,,Not detected,Tissue enriched,11,cerebral cortex: 60.0,testis: 5.3,Group enriched,12.0,SCLC-21H: 7.8;SH-SY5Y: 5.2
181,PCDH9,,ENSG00000184226,Protocadherin 9,13,66302834-67230445,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA015581,,,Approved,Nucleoplasm<br>Centrosome,,Tissue enriched,Tissue enriched,11,cerebral cortex: 68.8,seminal vesicle: 6.1,Cell line enhanced,,AF22: 24.9;LHCN-M2: 34.9;TIME: 40.1;U-698: 44.9
182,PCDHGB1,PCDH-GAMMA-B1,ENSG00000254221,"Protocadherin gamma subfamily B, 1",5,141350102-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA076182",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Focal adhesion sites<br>Midbody<br>Cytosol,,Mixed,Tissue enriched,11,cerebral cortex: 23.8,endometrium: 2.0,Cell line enhanced,,ASC diff: 8.8;T-47d: 8.1
183,PCDHGC4,PCDH-GAMMA-C4,ENSG00000242419,"Protocadherin gamma subfamily C, 4",5,141484997-141512979,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enriched,11,cerebral cortex: 16.3,adrenal gland: 1.4,Cell line enhanced,,REH: 8.3;SCLC-21H: 8.7;SH-SY5Y: 15.1
184,PDYN,"ADCA, PENKB, SCA23",ENSG00000101327,Prodynorphin,20,1978757-1994285,"Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA049841, HPA053342",Approved,Supported,,,,Group enriched,Tissue enriched,11,cerebral cortex: 63.3,testis: 5.5,Not detected,,
185,POU3F4,"BRN4, DFN3, DFNX2, OTF9",ENSG00000196767,POU class 3 homeobox 4,X,83508250-83512127,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA031984, HPA062295",Uncertain,,Supported,Nucleus,,Tissue enriched,Tissue enriched,11,cerebral cortex: 7.9,kidney: 0.7,Cell line enriched,96.0,AF22: 9.6
186,RPRML,MGC43894,ENSG00000179673,Reprimo like,17,46978156-46979248,Predicted membrane proteins,Evidence at transcript level,HPA062668,Uncertain,,,,,Tissue enhanced,Tissue enriched,11,cerebral cortex: 8.6,epididymis: 0.7,Cell line enhanced,,AF22: 1.9;Daudi: 8.9;HEK93: 3.5;NTERA-2: 1.9;SCLC-21H: 2.2
187,SCN3B,HSA243396,ENSG00000166257,Sodium voltage-gated channel beta subunit 3,11,123629187-123655244,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA041707,,,Approved,Intermediate filaments<br>Cytosol,,Tissue enhanced,Tissue enriched,11,cerebral cortex: 132.1,adrenal gland: 11.5,Cell line enhanced,,hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
188,SEPT3,SEP3,ENSG00000100167,Septin 3,22,41976272-41998221,Predicted intracellular proteins,Evidence at protein level,"HPA003548, CAB017633",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments,Endometrial cancer:1.78e-4 (unfavourable),Tissue enhanced,Tissue enriched,11,cerebral cortex: 234.8,parathyroid gland: 21.5,Cell line enhanced,,AF22: 26.2;SCLC-21H: 84.0
189,SLC8A2,"KIAA1087, NCX2",ENSG00000118160,Solute carrier family 8 member A2,19,47428017-47472168,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA050818, HPA054671",Enhanced,,,,,Mixed,Tissue enriched,11,cerebral cortex: 68.2,endometrium: 6.3,Group enriched,8.0,NTERA-2: 3.2;SCLC-21H: 10.8;SH-SY5Y: 5.2;SiHa: 4.1;U-2 OS: 6.2
190,SYP,MRX96,ENSG00000102003,Synaptophysin,X,49187804-49200259,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000076, HPA002858, CAB055505, CAB078999",Enhanced,Supported,,,,Group enriched,Tissue enriched,11,cerebral cortex: 571.4,adrenal gland: 51.1,Cell line enhanced,,SCLC-21H: 116.7;SH-SY5Y: 38.0
191,TRIM9,"RNF91, SPRING",ENSG00000100505,Tripartite motif containing 9,14,50975262-51096061,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041489,,,Supported,Cytosol,,Tissue enriched,Tissue enriched,11,cerebral cortex: 79.2,gallbladder: 6.9,Cell line enhanced,,AN3-CA: 29.8;HAP1: 23.6;HDLM-2: 33.8;SCLC-21H: 38.5
192,AC002429.5,,ENSG00000236197,,7,95035731-95214332,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,10,cerebral cortex: 2.7,esophagus: 0.2,Not detected,,
193,ADGRB1,BAI1,ENSG00000181790,Adhesion G protein-coupled receptor B1,8,142449430-142545009,"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 22.0,spleen: 2.2,Cell line enhanced,,AN3-CA: 10.7;RPMI-8226: 12.0;U-2 OS: 11.7
194,ADGRB3,"BAI3, KIAA0550",ENSG00000135298,Adhesion G protein-coupled receptor B3,6,68635367-69389511,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,10,cerebral cortex: 53.1,adrenal gland: 5.1,Group enriched,5.0,SCLC-21H: 10.4;SH-SY5Y: 20.2
195,ASIC1,"ACCN2, BNaC2, hBNaC2",ENSG00000110881,Acid sensing ion channel subunit 1,12,50057548-50083611,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA058870,,,Approved,Golgi apparatus<br>Plasma membrane,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 56.8,parathyroid gland: 5.7,Cell line enhanced,,SH-SY5Y: 30.8
196,B3GAT2,GlcAT-S,ENSG00000112309,"Beta-1,3-glucuronyltransferase 2",6,70856679-70957038,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA012059,Uncertain,,,,,Group enriched,Tissue enriched,10,cerebral cortex: 19.5,testis: 1.8,Cell line enriched,25.0,SCLC-21H: 25.9
197,CDK5R2,"NCK5AI, P39, p39nck5ai",ENSG00000171450,Cyclin dependent kinase 5 regulatory subunit 2,2,218959655-218962162,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 52.1,adrenal gland: 5.1,Group enriched,10.0,SCLC-21H: 21.4;SH-SY5Y: 14.0
198,DCLK2,"DCAMKL2, DCDC3, DCDC3B, DCK2, MGC45428",ENSG00000170390,Doublecortin like kinase 2,4,150078274-150257457,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015770,Enhanced,,,,"Pancreatic cancer:2.48e-4 (favourable), Ovarian cancer:3.25e-4 (favourable)",Tissue enriched,Tissue enriched,10,cerebral cortex: 82.6,heart muscle: 7.9,Cell line enhanced,,AF22: 23.3;BJ hTERT+: 20.2
199,DNAJC6,"KIAA0473, PARK19",ENSG00000116675,DnaJ heat shock protein family (Hsp40) member C6,1,65248219-65415869,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA031182, HPA054917",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.81e-4 (favourable),Tissue enhanced,Tissue enriched,10,cerebral cortex: 162.8,adrenal gland: 15.6,Cell line enhanced,,HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
200,FEZ1,UNC-76,ENSG00000149557,Fasciculation and elongation protein zeta 1,11,125445745-125496317,Predicted intracellular proteins,Evidence at protein level,HPA038490,,,Supported,Microtubules<br>Cytosol,"Renal cancer:2.16e-6 (unfavourable), Cervical cancer:9.06e-5 (unfavourable)",Tissue enriched,Tissue enriched,10,cerebral cortex: 410.9,urinary bladder: 41.3,Cell line enhanced,,AF22: 156.1;NTERA-2: 145.3;SCLC-21H: 181.1
201,GRIA4,"GluA4, GLUR4, GLURD",ENSG00000152578,Glutamate ionotropic receptor AMPA type subunit 4,11,105609994-105982092,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,10,cerebral cortex: 73.2,adrenal gland: 7.3,Cell line enhanced,,AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1
202,GRM2,"GPRC1B, mGlu2, MGLUR2",ENSG00000164082,Glutamate metabotropic receptor 2,3,51707070-51718613,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA027868, HPA065166",Approved,Supported,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 4.4,testis: 0.4,Cell line enriched,7.0,SCLC-21H: 7.3
203,ICAM5,"TLCN, TLN",ENSG00000105376,Intercellular adhesion molecule 5,19,10289981-10296778,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008943, HPA009083, CAB025178",Enhanced,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 21.6,lung: 2.0,Cell line enhanced,,HEL: 14.8;K-562: 12.0;RPMI-8226: 10.5;U-266/70: 13.3;U-87 MG: 10.1
204,KCNN1,"hSK1, KCa2.1",ENSG00000105642,Potassium calcium-activated channel subfamily N member 1,19,17951293-18000080,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA065938,,,Approved,Actin filaments<br>Cytosol,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 21.4,testis: 2.0,Cell line enriched,13.0,REH: 141.4
205,LHFPL3,LHFPL4,ENSG00000187416,Lipoma HMGIC fusion partner-like 3,7,104328656-104907232,Predicted membrane proteins,Evidence at transcript level,HPA069691,,,Approved,Vesicles,,Tissue enriched,Tissue enriched,10,cerebral cortex: 48.7,"cervix, uterine: 4.6",Cell line enhanced,,SCLC-21H: 1.8;SH-SY5Y: 2.1;SK-BR-3: 1.3
206,LRRTM2,KIAA0416,ENSG00000146006,Leucine rich repeat transmembrane neuronal 2,5,138868923-138875368,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,10,cerebral cortex: 29.0,placenta: 3.0,Group enriched,7.0,HDLM-2: 14.6;SCLC-21H: 5.8
207,NECAB1,EFCBP1,ENSG00000123119,N-terminal EF-hand calcium binding protein 1,8,90791550-90959408,Predicted intracellular proteins,Evidence at protein level,"HPA023252, HPA023629, HPA025963, HPA031262, CAB068208, CAB068209, CAB068210",Enhanced,Supported,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enriched,10,cerebral cortex: 79.7,lung: 8.1,Mixed,,
208,NEFL,"CMT1F, CMT2E, NF68, NFL, PPP1R110",ENSG00000277586,Neurofilament light,8,24950955-24957110,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA014850, HPA015021",Enhanced,Supported,Approved,Nuclear speckles<br>Intermediate filaments,Renal cancer:4.91e-4 (unfavourable),Tissue enhanced,Tissue enriched,10,cerebral cortex: 289.3,adrenal gland: 29.0,Cell line enhanced,,HEK93: 544.8;PC-3: 147.7
209,PCDHA5,"CNR6, CNRN6, CNRS6, CRNR6, PCDH-ALPHA5",ENSG00000204965,Protocadherin alpha 5,5,140821604-141012344,Predicted membrane proteins,Evidence at transcript level,HPA044557,Approved,,,,,Not detected,Tissue enriched,10,cerebral cortex: 4.1,endometrium: 0.4,Cell line enhanced,,A549: 1.2;EFO-21: 3.4;T-47d: 3.5;WM-115: 1.4
210,PLPPR4,"KIAA0455, LPPR4, PHP1, PRG-1",ENSG00000117600,Phospholipid phosphatase related 4,1,99263953-99309590,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 88.6,testis: 9.0,Cell line enhanced,,BJ hTERT+: 21.8;BJ hTERT+ SV40 Large T+ RasG12V: 10.0;SH-SY5Y: 21.1;U-138 MG: 9.8;U-87 MG: 16.4
211,RUNDC3A,"RAP2IP, RPIP8",ENSG00000108309,RUN domain containing 3A,17,44308413-44318671,Predicted intracellular proteins,Evidence at protein level,"HPA023548, HPA070733",Enhanced,Supported,Approved,Vesicles,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 178.0,adrenal gland: 18.2,Group enriched,8.0,SCLC-21H: 72.5;SH-SY5Y: 41.7
212,SERPINI1,"neuroserpin, PI12",ENSG00000163536,Serpin family I member 1,3,167735243-167825568,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001565, CAB026059, HPA056092",Enhanced,,Approved,Cytosol,Liver cancer:4.25e-4 (unfavourable),Expressed in all,Tissue enriched,10,cerebral cortex: 322.1,kidney: 31.3,Mixed,,
213,SH3GL2,"CNSA2, EEN-B1, SH3D2A, SH3P4",ENSG00000107295,"SH3 domain containing GRB2 like 2, endophilin A1",9,17579082-17797129,Predicted intracellular proteins,Evidence at protein level,"CAB010056, HPA026685, HPA063573",Enhanced,Supported,Approved,Microtubules<br>Cytokinetic bridge<br>Mitotic spindle,Renal cancer:6.68e-12 (favourable),Tissue enhanced,Tissue enriched,10,cerebral cortex: 170.1,kidney: 17.5,Cell line enhanced,,HeLa: 14.7;RT4: 34.0;SCLC-21H: 31.7
214,SLC6A17,,ENSG00000197106,Solute carrier family 6 member 17,1,110150486-110202202,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA007663, HPA008044",Enhanced,,Approved,Nucleus<br>Golgi apparatus,,Tissue enriched,Tissue enriched,10,cerebral cortex: 75.4,adrenal gland: 7.9,Cell line enhanced,,SiHa: 6.6;SK-MEL-30: 28.5;U-87 MG: 7.0
215,SLCO1C1,"OATP-F, OATP1, OATP1C1, SLC21A14",ENSG00000139155,Solute carrier organic anion transporter family member 1C1,12,20695355-20753386,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,10,cerebral cortex: 27.5,testis: 2.6,Cell line enriched,9.0,HeLa: 2.7
216,SYT3,,ENSG00000213023,Synaptotagmin 3,19,50621307-50639827,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enriched,10,cerebral cortex: 17.1,testis: 1.7,Cell line enhanced,,HEK93: 7.1;HMC-1: 4.7;NTERA-2: 5.5;SH-SY5Y: 6.6;U-2 OS: 4.0
217,SYT5,,ENSG00000129990,Synaptotagmin 5,19,55171199-55180441,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA078390,Enhanced,,,,"Pancreatic cancer:5.54e-4 (favourable), Glioma:8.26e-4 (unfavourable)",Mixed,Tissue enriched,10,cerebral cortex: 131.4,adrenal gland: 12.7,Cell line enhanced,,EFO-21: 25.6;HMC-1: 53.1;K-562: 20.2;SCLC-21H: 18.7
218,TMEM151B,"bA444E17.5, C6orf137, TMEM193",ENSG00000178233,Transmembrane protein 151B,6,44270466-44307506,Predicted membrane proteins,Evidence at transcript level,HPA055167,Uncertain,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 40.0,adrenal gland: 3.9,Cell line enriched,5.0,SCLC-21H: 33.6
219,TMEM257,CXorf1,ENSG00000221870,Transmembrane protein 257,X,145827410-145829850,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,10,cerebral cortex: 4.2,seminal vesicle: 0.4,Not detected,,
220,TPPP,"p25, p25alpha, TPPP/p25, TPPP1",ENSG00000171368,Tubulin polymerization promoting protein,5,659862-693395,Predicted intracellular proteins,Evidence at protein level,"HPA036575, HPA036576",Enhanced,,Supported,Mitochondria<br>Cytosol,Renal cancer:5.40e-6 (favourable),Expressed in all,Tissue enriched,10,cerebral cortex: 166.6,fallopian tube: 16.9,Cell line enhanced,,A549: 6.6;AN3-CA: 5.0;SCLC-21H: 15.6
221,XKR7,"C20orf159, dJ310O13.4",ENSG00000260903,XK related 7,20,31968002-32003387,Predicted membrane proteins,Evidence at protein level,HPA040854,Uncertain,,,,,Not detected,Tissue enriched,10,cerebral cortex: 3.6,"adrenal gland,testis: 0.3",Group enriched,18.0,SCLC-21H: 24.2;SH-SY5Y: 4.9
222,AK5,,ENSG00000154027,Adenylate kinase 5,1,77282051-77559969,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019128, HPA057255",Enhanced,,Supported,Microtubule organizing center<br>Cytosol,Prostate cancer:3.88e-4 (favourable),Group enriched,Tissue enriched,9,cerebral cortex: 220.7,breast: 23.6,Cell line enhanced,,ASC TERT1: 65.9;BJ: 57.0;fHDF/TERT166: 60.0;LHCN-M2: 159.8;U-2 OS: 61.3
223,AMER3,"FAM123C, FLJ38377",ENSG00000178171,APC membrane recruitment protein 3,2,130755435-130768134,Predicted intracellular proteins,Evidence at protein level,"HPA045593, HPA054230",Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 7.0,adrenal gland: 0.8,Cell line enriched,6.0,SCLC-21H: 12.2
224,AMPH,,ENSG00000078053,Amphiphysin,7,38383704-38631567,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008559, HPA019828, HPA019829",Enhanced,,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:9.96e-4 (favourable),Tissue enhanced,Tissue enriched,9,cerebral cortex: 83.7,"cervix, uterine: 8.9",Cell line enhanced,,ASC diff: 44.1;ASC TERT1: 26.4;BJ hTERT+ SV40 Large T+ RasG12V: 29.1;U-138 MG: 24.3
225,ATP1B2,AMOG,ENSG00000129244,ATPase Na+/K+ transporting subunit beta 2,17,7646627-7657768,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010698,Enhanced,,,,"Pancreatic cancer:1.05e-4 (favourable), Renal cancer:4.17e-4 (unfavourable)",Tissue enriched,Tissue enriched,9,cerebral cortex: 339.2,ovary: 36.7,Cell line enhanced,,AF22: 9.7;HAP1: 3.1;K-562: 4.2
226,CAMK2A,"CAMKA, CaMKIINalpha, KIAA0968",ENSG00000070808,Calcium/calmodulin dependent protein kinase II alpha,5,150219491-150290291,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004330, HPA051783, HPA051785, HPA053973",Enhanced,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Tissue enriched,Tissue enriched,9,cerebral cortex: 283.6,skeletal muscle: 33.3,Cell line enhanced,,SCLC-21H: 6.2;U-87 MG: 4.3
227,CELF4,BRUNOL4,ENSG00000101489,CUGBP Elav-like family member 4,18,37243047-37566037,Predicted intracellular proteins,Evidence at protein level,HPA037986,Approved,,,,,Mixed,Tissue enriched,9,cerebral cortex: 126.9,adrenal gland: 14.7,Group enriched,15.0,SCLC-21H: 51.8;SH-SY5Y: 11.4
228,CNKSR2,"CNK2, KIAA0902, KSR2",ENSG00000149970,Connector enhancer of kinase suppressor of Ras 2,X,21374418-21654695,Predicted intracellular proteins,Evidence at protein level,HPA001502,,,Approved,Golgi apparatus<br>Plasma membrane,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 53.9,adrenal gland: 5.8,Cell line enhanced,,A549: 6.4;NTERA-2: 10.9;RH-30: 9.6
229,DIRAS2,"Di-Ras2, DKFZp761C07121",ENSG00000165023,DIRAS family GTPase 2,9,90609832-90643105,Predicted intracellular proteins,Evidence at protein level,HPA043758,Uncertain,,,,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 128.3,"cervix, uterine: 13.9",Cell line enhanced,,AF22: 7.0;EFO-21: 1.9;SCLC-21H: 1.5
230,GABRA4,,ENSG00000109158,Gamma-aminobutyric acid type A receptor alpha4 subunit,4,46918900-46994407,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,9,cerebral cortex: 15.1,heart muscle: 1.6,Cell line enriched,127.0,REH: 12.7
231,KCNJ6,"BIR1, GIRK2, hiGIRK2, KATP2, KCNJ7, Kir3.2",ENSG00000157542,Potassium voltage-gated channel subfamily J member 6,21,37607376-37916446,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Not detected,Tissue enriched,9,cerebral cortex: 2.6,"spleen,stomach,testis: 0.2",Cell line enhanced,,LHCN-M2: 7.1;TIME: 1.8
232,LHFPL4,,ENSG00000156959,Lipoma HMGIC fusion partner-like 4,3,9498361-9553802,Predicted membrane proteins,Evidence at protein level,HPA041421,Uncertain,,Approved,Nucleus<br>Golgi apparatus,,Group enriched,Tissue enriched,9,cerebral cortex: 23.1,adrenal gland: 2.6,Cell line enhanced,,NTERA-2: 4.4;SCLC-21H: 11.9;SH-SY5Y: 13.4;U-266/84: 7.9;WM-115: 3.9
233,LINC02210-CRHR1,,ENSG00000263715,LINC02210-CRHR1 readthrough,17,45620344-45835826,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enriched,9,cerebral cortex: 1.1,fallopian tube: 0.1,Not detected,,
234,LLNLF-187D8.1,,ENSG00000277531,,19,46424697-46428951,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,9,cerebral cortex: 23.3,epididymis: 2.5,Group enriched,5.0,AF22: 1.1;HMC-1: 2.2;SH-SY5Y: 4.0
235,LRRTM4,FLJ12568,ENSG00000176204,Leucine rich repeat transmembrane neuronal 4,2,76747719-77593319,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 21.3,epididymis: 2.4,Cell line enriched,7.0,Karpas-707: 91.1
236,MAP1A,MAP1L,ENSG00000166963,Microtubule associated protein 1A,15,43510958-43531620,"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039063, HPA039064, HPA066488",Enhanced,,Approved,Cytosol,"Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable)",Tissue enhanced,Tissue enriched,9,cerebral cortex: 165.6,smooth muscle: 18.9,Cell line enhanced,,fHDF/TERT166: 72.9;U-87 MG: 119.0
237,MPPED1,"239AB, C22orf1, FAM1A",ENSG00000186732,Metallophosphoesterase domain containing 1,22,43411196-43507848,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 39.4,liver: 4.2,Cell line enhanced,,HaCaT: 5.9;SCLC-21H: 3.1
238,NAPB,"SNAP-BETA, SNAPB",ENSG00000125814,NSF attachment protein beta,20,23374519-23421519,Predicted intracellular proteins,Evidence at protein level,"CAB037225, CAB037227, HPA046149, HPA050196",Approved,,Uncertain,Cytosol,Renal cancer:1.14e-4 (unfavourable),Expressed in all,Tissue enriched,9,cerebral cortex: 303.2,adrenal gland: 32.1,Expressed in all,,
239,PAQR6,"FLJ22672, PRdelta",ENSG00000160781,Progestin and adipoQ receptor family member 6,1,156243321-156248117,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA073505,,,Approved,Nucleus<br>Nucleoli,"Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable)",Tissue enriched,Tissue enriched,9,cerebral cortex: 97.5,skin: 10.7,Cell line enhanced,,U-266/70: 19.6
240,PDZD4,"FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L",ENSG00000067840,PDZ domain containing 4,X,153802166-153830565,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA003878,Enhanced,,,,Pancreatic cancer:2.96e-5 (favourable),Tissue enhanced,Tissue enriched,9,cerebral cortex: 123.5,seminal vesicle: 13.7,Cell line enhanced,,AF22: 24.1;RH-30: 16.8;SCLC-21H: 34.7;SH-SY5Y: 30.4;U-2 OS: 14.9
241,PGM2L1,"BM32A, FLJ32029",ENSG00000165434,Phosphoglucomutase 2 like 1,11,74330318-74398473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA056995, HPA060948",Enhanced,,Approved,Mitochondria,,Mixed,Tissue enriched,9,cerebral cortex: 64.1,endometrium: 7.3,Cell line enhanced,,RH-30: 18.2
242,PHACTR3,"C20orf101, PPP1R123",ENSG00000087495,Phosphatase and actin regulator 3,20,59577509-59847711,Predicted intracellular proteins,Evidence at protein level,"HPA051834, HPA054847",,,Enhanced,Nucleoplasm,,Group enriched,Tissue enriched,9,cerebral cortex: 64.8,spleen: 7.4,Cell line enhanced,,RPTEC TERT1: 18.7;THP-1: 88.0;U-937: 25.4
243,PRKAR1B,,ENSG00000188191,Protein kinase cAMP-dependent type I regulatory subunit beta,7,549197-727650,Predicted intracellular proteins,Evidence at protein level,HPA026719,Approved,,,,,Expressed in all,Tissue enriched,9,cerebral cortex: 239.1,ovary: 26.3,Expressed in all,,
244,PRKCG,"MGC57564, PKCC, PKCG, SCA14",ENSG00000126583,Protein kinase C gamma,19,53879190-53907652,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB013051, HPA047870, HPA054560",Supported,,,,,Mixed,Tissue enriched,9,cerebral cortex: 40.9,testis: 4.7,Cell line enhanced,,A549: 2.0;SH-SY5Y: 1.5
245,PRR18,MGC35308,ENSG00000176381,Proline rich 18,6,166305300-166308448,Predicted intracellular proteins,Evidence at protein level,HPA077250,Enhanced,,,,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 32.6,fallopian tube: 3.4,Group enriched,11.0,SCLC-21H: 5.0;SH-SY5Y: 2.7
246,PRR36,,ENSG00000183248,Proline rich 36,19,7868719-7874379,Predicted intracellular proteins,Evidence at protein level,HPA062741,Uncertain,,Approved,Nucleus<br>Golgi apparatus,Testis cancer:7.74e-4 (favourable),Mixed,Tissue enriched,9,cerebral cortex: 18.0,prostate: 1.9,Cell line enhanced,,REH: 26.2;SCLC-21H: 9.4;SH-SY5Y: 19.0
247,PTPRZ1,"phosphacan, PTP18, PTPRZ, PTPZ, RPTPB",ENSG00000106278,"Protein tyrosine phosphatase, receptor type Z1",7,121873089-122062036,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA015103, CAB025106, HPA071024",Enhanced,Supported,Supported,Cytosol,Urothelial cancer:9.36e-4 (unfavourable),Tissue enriched,Tissue enriched,9,cerebral cortex: 257.9,skin: 30.1,Group enriched,12.0,AF22: 420.6;NTERA-2: 119.0;WM-115: 185.9
248,RLBP1,CRALBP,ENSG00000140522,Retinaldehyde binding protein 1,15,89209869-89221751,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA042051, HPA044083",Supported,Approved,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,,Group enriched,Tissue enriched,9,cerebral cortex: 6.1,testis: 0.6,Cell line enriched,53.0,SK-MEL-30: 16.5
249,RTP5,"C2orf85, CXXC11, FLJ33590, Z3CXXC5",ENSG00000188011,Receptor transporter protein 5 (putative),2,241869600-241873823,Predicted membrane proteins,Evidence at protein level,HPA050902,Approved,,,,,Tissue enriched,Tissue enriched,9,cerebral cortex: 5.3,lymph node: 0.5,Group enriched,21.0,MOLT-4: 1.1;SCLC-21H: 3.0
250,SMIM18,,ENSG00000253457,Small integral membrane protein 18,8,30638600-30646064,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA066648,Supported,,Uncertain,Nucleus<br>Centrosome,,Tissue enriched,Tissue enriched,9,cerebral cortex: 11.1,adrenal gland: 1.3,Cell line enriched,6.0,SH-SY5Y: 9.9
251,SPRN,"bA108K14.1, FLJ41197, Shadoo, Sprn",ENSG00000203772,Shadow of prion protein homolog (zebrafish),10,133420666-133424572,"Predicted secreted proteins, Transporters",Evidence at transcript level,,,,,,"Urothelial cancer:1.58e-7 (favourable), Pancreatic cancer:1.54e-6 (favourable), Renal cancer:3.95e-4 (unfavourable)",Expressed in all,Tissue enriched,9,cerebral cortex: 24.8,testis: 2.8,Mixed,,
252,SRRM4,"KIAA1853, nSR100",ENSG00000139767,Serine/arginine repetitive matrix 4,12,118981495-119163051,Predicted intracellular proteins,Evidence at protein level,HPA052783,Uncertain,,,,,Tissue enriched,Tissue enriched,9,cerebral cortex: 13.5,adrenal gland: 1.5,Group enriched,5.0,HeLa: 2.3;SCLC-21H: 4.6;SH-SY5Y: 3.3
253,TMOD2,NTMOD,ENSG00000128872,Tropomodulin 2,15,51751561-51816368,Predicted intracellular proteins,Evidence at protein level,HPA041365,Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center,Pancreatic cancer:4.53e-4 (favourable),Tissue enhanced,Tissue enriched,9,cerebral cortex: 111.0,seminal vesicle: 11.7,Cell line enhanced,,SCLC-21H: 43.4
254,TUBB2A,"dJ40E16.7, TUBB, TUBB2",ENSG00000137267,Tubulin beta 2A class IIa,6,3153669-3157526,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB015339, HPA043640, HPA046280",Supported,,Supported,Microtubules,"Urothelial cancer:1.61e-4 (unfavourable), Renal cancer:4.65e-4 (favourable)",Expressed in all,Tissue enriched,9,cerebral cortex: 622.8,skin: 72.0,Expressed in all,,
255,ZIC1,"ZIC, ZNF201",ENSG00000152977,Zic family member 1,3,147393422-147510293,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA004098,Supported,,Supported,Nucleoplasm,,Tissue enhanced,Tissue enriched,9,cerebral cortex: 23.8,skin: 2.5,Cell line enriched,5.0,AF22: 171.9
256,ANKRD34A,ANKRD34,ENSG00000272031,Ankyrin repeat domain 34A,1,145959442-145964582,Predicted intracellular proteins,Evidence at protein level,"HPA029642, HPA029643",Uncertain,,Enhanced,Cytosol,,Mixed,Tissue enriched,8,cerebral cortex: 12.7,"appendix,parathyroid gland: 1.6",Mixed,,
257,ANKS1B,"AIDA-1, ANKS2, cajalin-2, EB-1",ENSG00000185046,Ankyrin repeat and sterile alpha motif domain containing 1B,12,98726457-99984654,Predicted intracellular proteins,Evidence at protein level,HPA044628,,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 111.9,testis: 14.0,Cell line enhanced,,AF22: 10.0;SCLC-21H: 13.0
258,ARNT2,"bHLHe1, KIAA0307",ENSG00000172379,Aryl hydrocarbon receptor nuclear translocator 2,15,80404350-80597937,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001056, CAB005081",Enhanced,,Supported,Nucleus,"Pancreatic cancer:1.46e-6 (favourable), Renal cancer:7.51e-4 (favourable)",Expressed in all,Tissue enriched,8,cerebral cortex: 153.7,testis: 18.8,Mixed,,
259,ASIC4,"ACCN4, BNAC4",ENSG00000072182,Acid sensing ion channel subunit family member 4,2,219514170-219538772,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,8,cerebral cortex: 10.6,adrenal gland: 1.3,Group enriched,43.0,HEL: 17.6;HMC-1: 5.0;K-562: 10.2;SH-SY5Y: 5.4
260,BRINP1,"DBC1, DBCCR1, FAM5A",ENSG00000078725,BMP/retinoic acid inducible neural specific 1,9,119153458-119369467,"Predicted secreted proteins, Transporters",Evidence at protein level,HPA038828,Approved,,Approved,Microtubules,,Mixed,Tissue enriched,8,cerebral cortex: 59.6,seminal vesicle: 7.2,Cell line enhanced,,HSkMC: 6.2;NTERA-2: 16.8;SCLC-21H: 8.7
261,CACNA1E,"BII, CACH6, CACNL1A6, Cav2.3",ENSG00000198216,Calcium voltage-gated channel subunit alpha1 E,1,181413102-181808084,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA042515, CAB079032",,Approved,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,,Mixed,Tissue enriched,8,cerebral cortex: 10.3,adrenal gland: 1.3,Cell line enhanced,,CACO-2: 1.2;U-266/70: 1.5
262,CLEC19A,,ENSG00000261210,C-type lectin domain family 19 member A,16,19285739-19322145,Predicted secreted proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enriched,8,cerebral cortex: 3.2,skin: 0.4,Not detected,,
263,FAM131B,KIAA0773,ENSG00000159784,Family with sequence similarity 131 member B,7,143353400-143362770,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA021371, HPA029992",,,Enhanced,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enriched,8,cerebral cortex: 63.8,parathyroid gland: 7.5,Cell line enhanced,,CACO-2: 11.5;NTERA-2: 22.2;PC-3: 19.9;SCLC-21H: 25.4
264,FGFBP3,"C10orf13, MGC39320",ENSG00000174721,Fibroblast growth factor binding protein 3,10,91906589-91909483,Predicted secreted proteins,Evidence at protein level,HPA053943,Uncertain,,,,,Mixed,Tissue enriched,8,cerebral cortex: 19.5,thyroid gland: 2.5,Cell line enriched,11.0,AF22: 312.7
265,GRM5,"GPRC1E, mGlu5, MGLUR5, PPP1R86",ENSG00000168959,Glutamate metabotropic receptor 5,11,88504576-89065945,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,8,cerebral cortex: 27.2,testis: 3.2,Not detected,,
266,HCN1,"BCNG-1, BCNG1, HAC-2",ENSG00000164588,Hyperpolarization activated cyclic nucleotide gated potassium channel 1,5,45254950-45696498,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA019195,Enhanced,,,,,Not detected,Tissue enriched,8,cerebral cortex: 4.9,heart muscle: 0.6,Cell line enhanced,,WM-115: 1.0
267,HTR2A,"5-HT2A, HTR2",ENSG00000102468,5-hydroxytryptamine receptor 2A,13,46831550-46897076,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA014011,Enhanced,,,,,Not detected,Tissue enriched,8,cerebral cortex: 32.2,smooth muscle: 3.9,Cell line enhanced,,ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6
268,KCNC1,Kv3.1,ENSG00000129159,Potassium voltage-gated channel subfamily C member 1,11,17734774-17856804,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA047634, HPA048249",Enhanced,,Approved,Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 18.6,testis: 2.2,Cell line enhanced,,RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
269,MAPK8IP2,"IB2, JIP2, PRKM8IPL",ENSG00000008735,Mitogen-activated protein kinase 8 interacting protein 2,22,50600685-50613981,Predicted intracellular proteins,Evidence at protein level,HPA034780,Uncertain,,,,,Mixed,Tissue enriched,8,cerebral cortex: 78.2,adrenal gland: 10.0,Cell line enhanced,,SCLC-21H: 24.1;SH-SY5Y: 19.6
270,MAPT,"DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau",ENSG00000186868,Microtubule associated protein tau,17,45894382-46028334,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000151, HPA048895, HPA069524, HPA069570, CAB072344",Enhanced,,Supported,Nuclear speckles<br>Plasma membrane,,Group enriched,Tissue enriched,8,cerebral cortex: 116.2,skeletal muscle: 13.7,Cell line enhanced,,HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
271,MLC1,"KIAA0027, LVM, MLC, VL",ENSG00000100427,Megalencephalic leukoencephalopathy with subcortical cysts 1,22,50059391-50085902,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA003040, HPA067533",Enhanced,,,,,Tissue enriched,Tissue enriched,8,cerebral cortex: 180.8,bone marrow: 23.0,Cell line enhanced,,HL-60: 182.4;NB-4: 133.9;THP-1: 267.0;U-266/70: 101.9;U-266/84: 85.6
272,NIM1K,"MGC42105, NIM1",ENSG00000177453,NIM1 serine/threonine protein kinase,5,43192071-43280850,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA007695,Uncertain,,Approved,Cytosol,,Tissue enriched,Tissue enriched,8,cerebral cortex: 16.3,lung: 2.0,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 1.9;HDLM-2: 2.1;PC-3: 2.4;U-87 MG: 2.6
273,NRXN2,,ENSG00000110076,Neurexin 2,11,64606174-64723188,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 142.6,testis: 17.0,Cell line enhanced,,REH: 43.5;SCLC-21H: 27.0;U-2 OS: 27.6;U-87 MG: 18.3
274,OLFM1,"AMY, NOE1, NOELIN, OlfA",ENSG00000130558,Olfactomedin 1,9,135075422-135121179,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA057444,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,"Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)",Expressed in all,Tissue enriched,8,cerebral cortex: 729.9,epididymis: 86.4,Cell line enhanced,,NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2
275,OPCML,"IGLON1, OBCAM, OPCM",ENSG00000183715,Opioid binding protein/cell adhesion molecule like,11,132414977-133532519,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,8,cerebral cortex: 63.0,parathyroid gland: 7.5,Cell line enhanced,,BJ: 7.9;HDLM-2: 1.8
276,PCDH8,"ARCADLIN, PAPC",ENSG00000136099,Protocadherin 8,13,52842889-52848641,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA010509,Uncertain,,Uncertain,Golgi apparatus<br>Cytosol,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 5.7,testis: 0.7,Group enriched,7.0,AF22: 23.5;NTERA-2: 4.9;SCLC-21H: 6.4
277,PRMT8,"HRMT1L3, HRMT1L4",ENSG00000111218,Protein arginine methyltransferase 8,12,3381349-3593973,Predicted intracellular proteins,Evidence at protein level,"HPA039747, HPA069769",Enhanced,,,,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 19.9,testis: 2.4,Cell line enriched,11.0,hTERT-HME1: 37.3
278,PRRT1,"C6orf31, IFITMD7, NG5",ENSG00000204314,Proline rich transmembrane protein 1,6,32148359-32154373,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA055149, HPA059099",Enhanced,,,,,Mixed,Tissue enriched,8,cerebral cortex: 4.5,ovary: 0.6,Cell line enhanced,,SK-MEL-30: 1.1
279,RFPL1,RNF78,ENSG00000128250,Ret finger protein like 1,22,29438583-29442455,Predicted intracellular proteins,Evidence at transcript level,"HPA048320, HPA072380",,,Approved,Nuclear speckles<br>Plasma membrane,,Not detected,Tissue enriched,8,cerebral cortex: 27.8,adrenal gland: 3.6,Cell line enhanced,,HDLM-2: 6.6;HMC-1: 2.3;Karpas-707: 2.0;SH-SY5Y: 3.5;THP-1: 2.2
280,RIPPLY2,"C6orf159, dJ237I15.1",ENSG00000203877,Ripply transcriptional repressor 2,6,83853266-83857515,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047454,Uncertain,,,,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 14.9,adrenal gland: 1.8,Cell line enhanced,,SCLC-21H: 30.7;SH-SY5Y: 18.9
281,RTN1,NSP,ENSG00000139970,Reticulon 1,14,59595976-59870966,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002745, HPA040945, HPA044249",Enhanced,,Enhanced,Endoplasmic reticulum,Pancreatic cancer:3.69e-4 (favourable),Tissue enhanced,Tissue enriched,8,cerebral cortex: 411.6,parathyroid gland: 49.6,Cell line enhanced,,HEL: 54.3;SCLC-21H: 84.4;SH-SY5Y: 121.8
282,SLC12A5,"KCC2, KIAA1176",ENSG00000124140,Solute carrier family 12 member 5,20,46021690-46060152,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA072058,Enhanced,,,,Glioma:8.45e-4 (unfavourable),Mixed,Tissue enriched,8,cerebral cortex: 94.2,adrenal gland: 11.9,Cell line enhanced,,NB-4: 32.3;U-2 OS: 29.1
283,SLC7A14,"KIAA1613, PPP1R142",ENSG00000013293,Solute carrier family 7 member 14,3,170459584-170586074,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA045929,Approved,,,,,Group enriched,Tissue enriched,8,cerebral cortex: 26.7,adrenal gland: 3.1,Cell line enhanced,,LHCN-M2: 2.7;SCLC-21H: 3.7
284,SOX2,,ENSG00000181449,SRY-box 2,3,181711924-181714436,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB010648, HPA045725, HPA071379",Approved,Supported,Supported,Nucleoplasm,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 117.9,esophagus: 14.8,Cell line enhanced,,AF22: 273.3;HAP1: 122.7;NTERA-2: 226.0
285,STXBP1,"hUNC18, MUNC18-1, rbSec1, UNC18",ENSG00000136854,Syntaxin binding protein 1,9,127579370-127696027,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008209, HPA023483, CAB034434",Enhanced,,Approved,Nucleoplasm<br>Cytosol,"Head and neck cancer:1.47e-4 (unfavourable), Endometrial cancer:4.78e-4 (unfavourable), Liver cancer:5.73e-4 (unfavourable), Pancreatic cancer:9.81e-4 (favourable)",Expressed in all,Tissue enriched,8,cerebral cortex: 396.3,fallopian tube: 52.6,Cell line enhanced,,SCLC-21H: 169.1
286,TAGLN3,"NP22, NP25",ENSG00000144834,Transgelin 3,3,111998664-112013887,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA062620,Enhanced,,,,,Tissue enhanced,Tissue enriched,8,cerebral cortex: 356.0,adrenal gland: 42.3,Group enriched,6.0,AF22: 98.0;RPTEC TERT1: 30.7;SCLC-21H: 63.4;SH-SY5Y: 96.4
287,AGAP2,CENTG1,ENSG00000135439,"ArfGAP with GTPase domain, ankyrin repeat and PH domain 2",12,57723761-57742157,Predicted intracellular proteins,Evidence at protein level,HPA023474,Approved,,Supported,Nucleus<br>Nucleoli<br>Mitochondria,,Tissue enriched,Tissue enriched,7,cerebral cortex: 144.5,lymph node: 19.8,Cell line enhanced,,RH-30: 95.5
288,ALDOC,,ENSG00000109107,"Aldolase, fructose-bisphosphate C",17,28573115-28577264,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003282, CAB020828, HPA067442",Enhanced,Supported,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)",Tissue enriched,Tissue enriched,7,cerebral cortex: 766.6,heart muscle: 111.2,Cell line enhanced,,RPMI-8226: 165.2;U-266/70: 119.9
289,ATOH7,"bHLHa13, Math5",ENSG00000179774,Atonal bHLH transcription factor 7,10,68230624-68232103,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA027008,Uncertain,,,,,Not detected,Tissue enriched,7,cerebral cortex: 2.2,"endometrium,kidney,small intestine: 0.3",Cell line enriched,14.0,SCLC-21H: 9.1
290,ATP2B2,PMCA2,ENSG00000157087,ATPase plasma membrane Ca2+ transporting 2,3,10324023-10708031,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB005606,Enhanced,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 64.7,salivary gland: 9.7,Group enriched,7.0,EFO-21: 3.0;RPMI-8226: 5.4;SCLC-21H: 4.2;SH-SY5Y: 1.2
291,BSN,ZNF231,ENSG00000164061,Bassoon presynaptic cytomatrix protein,3,49554489-49671545,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA034757,Approved,,,,,Mixed,Tissue enriched,7,cerebral cortex: 28.2,testis: 4.2,Cell line enhanced,,K-562: 1.7;SCLC-21H: 5.1;SH-SY5Y: 2.9
292,CABP1,,ENSG00000157782,Calcium binding protein 1,12,120640552-120667324,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051438,Uncertain,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 77.4,adipose tissue: 11.2,Cell line enhanced,,NTERA-2: 6.8;SCLC-21H: 3.8;U-87 MG: 8.4
293,CDK5R1,"Nck5a, p35, p35nck5a",ENSG00000176749,Cyclin dependent kinase 5 regulatory subunit 1,17,32486619-32491256,Predicted intracellular proteins,Evidence at protein level,HPA000252,,,Supported,Nucleoplasm<br>Vesicles,,Mixed,Tissue enriched,7,cerebral cortex: 98.4,lymph node: 14.7,Cell line enhanced,,SCLC-21H: 62.8;SK-MEL-30: 30.8
294,CELF5,BRUNOL5,ENSG00000161082,CUGBP Elav-like family member 5,19,3224703-3297076,Predicted intracellular proteins,Evidence at protein level,"HPA042012, HPA060336",Enhanced,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 38.1,ovary: 5.1,Cell line enhanced,,NTERA-2: 3.5;REH: 4.0;SCLC-21H: 5.2;SH-SY5Y: 2.8
295,CHD5,,ENSG00000116254,Chromodomain helicase DNA binding protein 5,1,6101793-6180123,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015809, HPA055477",Supported,,Supported,Nucleoplasm<br>Nuclear speckles<br>Cytosol,,Mixed,Tissue enriched,7,cerebral cortex: 42.1,testis: 6.2,Cell line enhanced,,SCLC-21H: 16.0;U-2 OS: 6.3
296,CNTN2,"AXT, TAG-1, TAX, TAX1",ENSG00000184144,Contactin 2,1,205042937-205078284,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA001397, HPA012497",Approved,,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 81.7,testis: 11.2,Group enriched,7.0,NTERA-2: 3.8;SCLC-21H: 11.1
297,COL20A1,KIAA1510,ENSG00000101203,Collagen type XX alpha 1 chain,20,63293186-63334851,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051962,Uncertain,,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 16.2,testis: 2.3,Not detected,,
298,DLEU7,FLJ44882,ENSG00000186047,"Deleted in lymphocytic leukemia, 7",13,50711008-50843939,Predicted intracellular proteins,Evidence at transcript level,HPA053750,Uncertain,,,,,Mixed,Tissue enriched,7,cerebral cortex: 6.3,epididymis: 0.9,Group enriched,7.0,NTERA-2: 11.0;U-698: 3.4
299,ELFN2,"dJ63G5.3, KIAA1904, LRRC62, PPP1R29",ENSG00000166897,Extracellular leucine rich repeat and fibronectin type III domain containing 2,22,37367960-37427470,Predicted membrane proteins,Evidence at protein level,HPA000781,Approved,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:7.21e-4 (unfavourable),Mixed,Tissue enriched,7,cerebral cortex: 24.3,testis: 3.4,Cell line enhanced,,RPTEC TERT1: 16.3;U-2 OS: 25.4
300,ENO2,,ENSG00000111674,Enolase 2,12,6913745-6923698,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000063, HPA068284, HPA068721, CAB073539, CAB079023",Enhanced,Supported,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 431.0,parathyroid gland: 64.8,Cell line enhanced,,U-87 MG: 368.8
301,FAIM2,"KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2",ENSG00000135472,Fas apoptotic inhibitory molecule 2,12,49866896-49904217,Predicted membrane proteins,Evidence at protein level,"HPA018790, HPA048800",Enhanced,,Approved,Intermediate filaments,,Tissue enriched,Tissue enriched,7,cerebral cortex: 369.7,adrenal gland: 55.7,Cell line enhanced,,HHSteC: 10.2;U-87 MG: 37.7
302,GABRA2,,ENSG00000151834,Gamma-aminobutyric acid type A receptor alpha2 subunit,4,46248427-46475230,"FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,CAB079061,,Supported,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 74.3,epididymis: 11.3,Cell line enhanced,,U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
303,GABRA3,,ENSG00000011677,Gamma-aminobutyric acid type A receptor alpha3 subunit,X,152166234-152451358,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA000839,Approved,Supported,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 28.8,placenta: 4.1,Cell line enhanced,,HMC-1: 7.4;Karpas-707: 10.3;PC-3: 7.8;U-2 OS: 7.3;U-266/84: 9.5;U-87 MG: 8.1
304,GDF1,,ENSG00000130283,Growth differentiation factor 1,19,18868545-18896096,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,7,cerebral cortex: 12.2,testis: 1.7,Cell line enhanced,,EFO-21: 2.8;HEK93: 3.3;NB-4: 3.1;NTERA-2: 2.4;SCLC-21H: 2.4
305,GNAO1,G-ALPHA-o,ENSG00000087258,G protein subunit alpha o1,16,56191347-56357457,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008387, HPA040878",Enhanced,,,,Pancreatic cancer:5.93e-4 (favourable),Tissue enriched,Tissue enriched,7,cerebral cortex: 166.9,seminal vesicle: 22.6,Cell line enhanced,,BJ hTERT+: 24.8;BJ hTERT+ SV40 Large T+: 18.7;SCLC-21H: 72.2
306,GPR52,,ENSG00000203737,G protein-coupled receptor 52,1,174448111-174449198,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA028575,Uncertain,,,,,Not detected,Tissue enriched,7,cerebral cortex: 2.6,bone marrow: 0.3,Not detected,,
307,GPRIN1,"GRIN1, KIAA1893",ENSG00000169258,G protein regulated inducer of neurite outgrowth 1,5,176595802-176610133,Predicted intracellular proteins,Evidence at protein level,"HPA036478, HPA070892",Enhanced,,Supported,Vesicles<br>Plasma membrane,"Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 27.8,duodenum: 3.8,Cell line enhanced,,HDLM-2: 52.6;SCLC-21H: 70.4
308,GRIA2,"GluA2, GLUR2, GLURB",ENSG00000120251,Glutamate ionotropic receptor AMPA type subunit 2,4,157204182-157366075,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB007812, HPA008441",Enhanced,,,,,Group enriched,Tissue enriched,7,cerebral cortex: 206.6,endometrium: 27.5,Cell line enriched,8.0,SCLC-21H: 19.9
309,HEPN1,,ENSG00000221932,"Hepatocellular carcinoma, down-regulated 1",11,124919244-124920677,Predicted intracellular proteins,Evidence at transcript level,"HPA043768, HPA063054",Uncertain,,Approved,Golgi apparatus,,Not detected,Tissue enriched,7,cerebral cortex: 79.5,adipose tissue: 11.1,Cell line enriched,358.0,Hep G2: 35.7
310,HMP19,,ENSG00000170091,HMP19 protein,5,174045604-174243501,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046531, HPA056191",Enhanced,,Supported,Golgi apparatus,,Tissue enriched,Tissue enriched,7,cerebral cortex: 288.5,adrenal gland: 42.0,Group enriched,84.0,SCLC-21H: 45.2;SH-SY5Y: 65.3
311,HS3ST4,3OST4,ENSG00000182601,Heparan sulfate-glucosamine 3-sulfotransferase 4,16,25692026-26137688,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enriched,7,cerebral cortex: 18.7,breast: 2.8,Cell line enhanced,,NTERA-2: 1.4
312,KCNH7,"erg3, HERG3, Kv11.3",ENSG00000184611,Potassium voltage-gated channel subfamily H member 7,2,162371407-162838730,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA018039,Uncertain,,,,,Not detected,Tissue enriched,7,cerebral cortex: 4.7,"stomach,testis: 0.6",Group enriched,12.0,SCLC-21H: 7.7;SK-BR-3: 4.4
313,KCNQ2,"BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2",ENSG00000075043,Potassium voltage-gated channel subfamily Q member 2,20,63400210-63472677,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA016642, HPA057112",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enriched,Tissue enriched,7,cerebral cortex: 57.2,testis: 8.2,Cell line enhanced,,AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1
314,KIAA0513,,ENSG00000135709,KIAA0513,16,85027751-85094230,Predicted intracellular proteins,Evidence at protein level,"HPA012866, HPA014431",Enhanced,,Uncertain,Nucleoplasm<br>Cytosol,Pancreatic cancer:1.72e-5 (favourable),Expressed in all,Tissue enriched,7,cerebral cortex: 102.6,adrenal gland: 14.9,Mixed,,
315,LRRC4C,"KIAA1580, NGL-1",ENSG00000148948,Leucine rich repeat containing 4C,11,40114203-41459773,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA051335, HPA054800",Approved,,Approved,Cytosol,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 34.4,"cervix, uterine: 4.7",Group enriched,9.0,AF22: 18.9;U-2 OS: 21.7
316,MEGF10,KIAA1780,ENSG00000145794,Multiple EGF like domains 10,5,127290831-127465737,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 15.8,adrenal gland: 2.2,Cell line enhanced,,AF22: 31.3;RH-30: 37.5
317,RIMS3,"NIM3, RIM3",ENSG00000117016,Regulating synaptic membrane exocytosis 3,1,40620679-40665657,Predicted intracellular proteins,Evidence at protein level,HPA055285,,,Approved,Nucleoli<br>Mitochondria,,Mixed,Tissue enriched,7,cerebral cortex: 60.4,adrenal gland: 8.3,Cell line enhanced,,Daudi: 55.3;SCLC-21H: 23.5;SH-SY5Y: 37.4;U-87 MG: 31.5
318,RPH3A,"exophilin-1, KIAA0985, rabphilin",ENSG00000089169,Rabphilin 3A,12,112570380-112898881,Predicted intracellular proteins,Evidence at protein level,HPA002475,Enhanced,,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 95.2,bone marrow: 13.8,Cell line enhanced,,SH-SY5Y: 17.7
319,SCN3A,Nav1.3,ENSG00000153253,Sodium voltage-gated channel alpha subunit 3,2,165087522-165204067,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA035396,Approved,,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 13.6,adrenal gland: 1.9,Cell line enhanced,,Karpas-707: 7.8;MOLT-4: 26.0;RPTEC TERT1: 11.6;SH-SY5Y: 7.3
320,SCN8A,"CerIII, MED, NaCh6, Nav1.6, PN4",ENSG00000196876,Sodium voltage-gated channel alpha subunit 8,12,51590266-51812864,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Mixed,Tissue enriched,7,cerebral cortex: 22.1,testis: 3.1,Mixed,,
321,SCRT1,"DKFZp547F072, ZNF898",ENSG00000261678,Scratch family transcriptional repressor 1,8,144330565-144336281,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA045265,Uncertain,,Supported,Nuclear bodies,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 10.9,adrenal gland: 1.5,Group enriched,12.0,SCLC-21H: 11.4;SH-SY5Y: 2.3
322,SEC14L5,"KIAA0420, PRELID4B",ENSG00000103184,SEC14 like lipid binding 5,16,4958317-5019158,Predicted intracellular proteins,Evidence at protein level,"HPA041492, HPA041825",,,Uncertain,Golgi apparatus<br>Cytosol,,Mixed,Tissue enriched,7,cerebral cortex: 17.1,heart muscle: 2.3,Cell line enhanced,,SCLC-21H: 3.2;T-47d: 1.7
323,SEZ6L,,ENSG00000100095,Seizure related 6 homolog like,22,26169474-26383597,Predicted membrane proteins,Evidence at protein level,HPA045135,,,Approved,Vesicles,,Group enriched,Tissue enriched,7,cerebral cortex: 89.2,adrenal gland: 13.6,Group enriched,8.0,SCLC-21H: 49.2;SH-SY5Y: 11.9
324,SLC24A2,NCKX2,ENSG00000155886,Solute carrier family 24 member 2,9,19507452-19786928,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 51.6,adrenal gland: 7.9,Cell line enhanced,,K-562: 2.3;SCLC-21H: 2.6;U-87 MG: 2.9
325,SNAP91,"AP180, CALM, KIAA0656",ENSG00000065609,Synaptosome associated protein 91,6,83552880-83709691,Predicted intracellular proteins,Evidence at protein level,"CAB009745, HPA029632, HPA029633",Enhanced,,Uncertain,Centrosome<br>Cytosol,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 152.1,testis: 22.5,Group enriched,16.0,SCLC-21H: 27.9;SH-SY5Y: 15.7
326,SOGA3,"C6orf174, dJ403A15.3",ENSG00000214338,SOGA family member 3,6,127472794-127519191,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035388, HPA035389",Uncertain,,Approved,Nucleus<br>Cytosol,,Not detected,Tissue enriched,7,cerebral cortex: 10.1,"ovary,stomach: 1.5",Cell line enhanced,,SCLC-21H: 36.7;SH-SY5Y: 18.9
327,ST18,"KIAA0535, NZF3, ZC2H2C3, ZC2HC10, ZNF387",ENSG00000147488,"ST18, C2H2C-type zinc finger",8,52110839-52460959,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA044919,Uncertain,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 11.6,stomach: 1.5,Cell line enhanced,,HAP1: 2.8;SCLC-21H: 11.3;U-87 MG: 1.5
328,ST8SIA3,SIAT8C,ENSG00000177511,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3",18,57350813-57371731,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA063398, HPA066783",Supported,,Supported,Golgi apparatus,,Group enriched,Tissue enriched,7,cerebral cortex: 31.8,adrenal gland: 4.8,Group enriched,67.0,NTERA-2: 4.3;SCLC-21H: 8.6;SH-SY5Y: 8.7
329,SYNGR3,,ENSG00000127561,Synaptogyrin 3,16,1989660-1994275,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB034278, HPA042842",Enhanced,,Approved,Plasma membrane,"Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable)",Mixed,Tissue enriched,7,cerebral cortex: 82.6,parathyroid gland: 12.6,Cell line enhanced,,HDLM-2: 45.7;HMC-1: 26.7;U-266/70: 30.7
330,TMEM132B,"KIAA1786, KIAA1906",ENSG00000139364,Transmembrane protein 132B,12,125186836-125662377,Predicted membrane proteins,Evidence at protein level,"HPA035661, HPA035662",Uncertain,,,,,Tissue enriched,Tissue enriched,7,cerebral cortex: 21.8,thyroid gland: 3.1,Cell line enhanced,,HSkMC: 4.8;NTERA-2: 7.7;U-138 MG: 11.6
331,UCHL1,"PARK5, PGP9.5, Uch-L1",ENSG00000154277,Ubiquitin C-terminal hydrolase L1,4,41256413-41268455,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002580, HPA005993, CAB079024",Enhanced,Supported,Enhanced,Nucleoplasm<br>Cytosol,"Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 785.9,adrenal gland: 107.9,Cell line enhanced,,EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2
332,YWHAH,YWHA1,ENSG00000128245,Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta,22,31944461-31957603,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB025918,Uncertain,,,,Liver cancer:1.59e-5 (unfavourable),Expressed in all,Tissue enriched,7,cerebral cortex: 896.7,lung: 137.7,Expressed in all,,
333,ABCA2,ABC2,ENSG00000107331,ATP binding cassette subfamily A member 2,9,137007227-137028922,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA042886,Approved,,,,,Expressed in all,Tissue enriched,6,cerebral cortex: 97.9,thyroid gland: 17.1,Cell line enhanced,,T-47d: 63.1
334,ADARB2,"ADAR3, hRED2, RED2",ENSG00000185736,"Adenosine deaminase, RNA specific B2 (inactive)",10,1177318-1737476,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enriched,6,cerebral cortex: 13.1,testis: 2.1,Not detected,,
335,ANKRD63,,ENSG00000230778,Ankyrin repeat domain 63,15,40281444-40282586,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enriched,6,cerebral cortex: 1.0,"fallopian tube,kidney,spleen,testis: 0.1",Cell line enhanced,,HEK93: 1.8
336,ARPP21,"ARPP-21, R3HDM3, TARPP",ENSG00000172995,CAMP regulated phosphoprotein 21,3,35638945-35794496,Predicted intracellular proteins,Evidence at protein level,HPA017303,Enhanced,,Approved,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 127.1,skeletal muscle: 20.2,Group enriched,10.0,MOLT-4: 54.6;REH: 34.0;RH-30: 19.9
337,B4GALNT1,"beta1-4GalNAc-T, GALGT, SPG26",ENSG00000135454,"Beta-1,4-N-acetyl-galactosaminyltransferase 1",12,57623410-57633355,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008968, HPA015128",Enhanced,,,,Renal cancer:3.18e-14 (unfavourable),Tissue enriched,Tissue enriched,6,cerebral cortex: 26.2,seminal vesicle: 4.0,Cell line enhanced,,EFO-21: 33.8;HDLM-2: 29.7
338,BEND6,"bA203B9.1, C6orf65, FLJ30162",ENSG00000151917,BEN domain containing 6,6,56955126-57027342,Predicted intracellular proteins,Evidence at protein level,"HPA031605, HPA052973",Enhanced,,Approved,Nucleus<br>Plasma membrane,,Tissue enriched,Tissue enriched,6,cerebral cortex: 39.2,"cervix, uterine: 6.6",Mixed,,
339,BRSK1,KIAA1811,ENSG00000160469,BR serine/threonine kinase 1,19,55282072-55312533,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021212, HPA061719",Supported,,Supported,Nucleoplasm,"Renal cancer:7.98e-6 (unfavourable), Pancreatic cancer:1.02e-4 (favourable)",Expressed in all,Tissue enriched,6,cerebral cortex: 137.8,parathyroid gland: 24.6,Cell line enhanced,,SCLC-21H: 65.8;SH-SY5Y: 53.1
340,CLASP2,KIAA0627,ENSG00000163539,Cytoplasmic linker associated protein 2,3,33496245-33718356,Predicted intracellular proteins,Evidence at protein level,HPA067071,,,Supported,Golgi apparatus<br>Cytosol,Renal cancer:1.48e-6 (favourable),Expressed in all,Tissue enriched,6,cerebral cortex: 193.2,endometrium: 34.2,Expressed in all,,
341,DAGLA,"C11orf11, DAGLALPHA, KIAA0659, NSDDR",ENSG00000134780,Diacylglycerol lipase alpha,11,61680433-61747001,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA062497,Approved,,,,Endometrial cancer:1.13e-7 (unfavourable),Expressed in all,Tissue enriched,6,cerebral cortex: 18.6,"colon,testis: 3.0",Mixed,,
342,DGKB,"DAGK2, DGK, DGK-BETA, KIAA0718",ENSG00000136267,Diacylglycerol kinase beta,7,14145049-14974777,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020321,,Supported,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 34.2,endometrium: 5.6,Cell line enhanced,,AF22: 1.2;fHDF/TERT166: 2.0;SCLC-21H: 1.5;U-266/70: 2.5
343,DLG4,"PSD-95, PSD95, SAP-90, SAP90",ENSG00000132535,Discs large MAGUK scaffold protein 4,17,7189890-7219702,"Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB001999, CAB002000, HPA010122",Enhanced,,Approved,Vesicles,"Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enriched,6,cerebral cortex: 178.6,endometrium: 28.9,Cell line enhanced,,HMC-1: 57.4
344,DLGAP1,"DAP-1, GKAP, SAPAP1",ENSG00000170579,DLG associated protein 1,18,3496032-4455335,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enriched,6,cerebral cortex: 91.2,seminal vesicle: 14.6,Cell line enhanced,,Daudi: 7.6;HAP1: 3.8;U-2197: 3.0
345,DRP2,,ENSG00000102385,Dystrophin related protein 2,X,101219769-101264497,Predicted intracellular proteins,Evidence at protein level,HPA002949,,,Approved,Nuclear speckles<br>Plasma membrane,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 12.3,prostate: 2.2,Cell line enhanced,,RH-30: 10.4;TIME: 15.0;U-87 MG: 4.3
346,FAM155A,,ENSG00000204442,Family with sequence similarity 155 member A,13,107163510-107866735,Predicted membrane proteins,Evidence at protein level,"HPA039453, HPA058768",Enhanced,,Approved,Nucleus<br>Vesicles<br>Centrosome,,Mixed,Tissue enriched,6,cerebral cortex: 15.6,seminal vesicle: 2.4,Cell line enhanced,,RPTEC TERT1: 9.3;SCLC-21H: 8.9;SH-SY5Y: 18.1;U-87 MG: 10.5
347,FAM163B,C9orf166,ENSG00000196990,Family with sequence similarity 163 member B,9,133578415-133586197,Predicted membrane proteins,Evidence at transcript level,HPA067336,Approved,,Approved,Nuclear bodies<br>Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enriched,6,cerebral cortex: 103.5,adrenal gland: 16.4,Cell line enriched,19.0,SH-SY5Y: 72.4
348,FAM171B,"FLJ34104, KIAA1946",ENSG00000144369,Family with sequence similarity 171 member B,2,186693971-186765965,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA010639, HPA013434",Approved,,Approved,Nucleus<br>Mitochondria,"Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)",Tissue enriched,Tissue enriched,6,cerebral cortex: 114.5,parathyroid gland: 19.3,Mixed,,
349,FAM19A1,"TAFA-1, TAFA1",ENSG00000183662,"Family with sequence similarity 19 member A1, C-C motif chemokine like",3,68004216-68545625,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA013407,Approved,,,,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 30.8,seminal vesicle: 5.3,Cell line enriched,9.0,REH: 1.5
350,FOXG1,"BF1, FKH2, FKHL1, FKHL2, FKHL3, FKHL4, FOXG1A, FOXG1B, FOXG1C, HBF-3, HFK1, HFK2, HFK3, QIN",ENSG00000176165,Forkhead box G1,14,28760330-28770277,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 29.6,testis: 5.2,Cell line enhanced,,HEK93: 10.3;SCLC-21H: 34.2;U-138 MG: 17.5;U-251 MG: 15.3
351,GAD1,GAD,ENSG00000128683,Glutamate decarboxylase 1,2,170813213-170861151,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004415, HPA031949, HPA058412, CAB078176",Enhanced,Supported,Approved,Vesicles,"Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)",Tissue enhanced,Tissue enriched,6,cerebral cortex: 75.3,parathyroid gland: 11.8,Cell line enhanced,,HEL: 55.7
352,GRIA1,"GluA1, GLUR1, GLURA",ENSG00000155511,Glutamate ionotropic receptor AMPA type subunit 1,5,153489615-153813869,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB001965, HPA035202",Supported,,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 67.1,lung: 10.6,Cell line enhanced,,AF22: 11.5;BJ: 4.7;LHCN-M2: 6.9;U-266/70: 4.4
353,GRIK3,"GluK3, GLUR7",ENSG00000163873,Glutamate ionotropic receptor kainate type subunit 3,1,36795527-37034129,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 19.8,seminal vesicle: 3.5,Group enriched,5.0,SCLC-21H: 11.4;T-47d: 37.2
354,HTR2C,"5-HT2C, 5HTR2C, HTR1C",ENSG00000147246,5-hydroxytryptamine receptor 2C,X,114584078-114910061,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 3.1,"cervix, uterine: 0.5",Cell line enhanced,,EFO-21: 2.5;U-266/70: 3.6;U-266/84: 2.8
355,INA,"NEF5, NF-66",ENSG00000148798,Internexin neuronal intermediate filament protein alpha,10,103277163-103290351,Predicted intracellular proteins,Evidence at protein level,"CAB002059, HPA008057",Enhanced,Supported,Supported,Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 89.0,adrenal gland: 16.0,Cell line enhanced,,NTERA-2: 53.4;SCLC-21H: 122.4;SH-SY5Y: 62.7;SiHa: 76.3
356,JAKMIP1,"FLJ31564, Gababrbp, JAMIP1, MARLIN1",ENSG00000152969,Janus kinase and microtubule interacting protein 1,4,6026199-6200591,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA044570,Uncertain,,,,,Mixed,Tissue enriched,6,cerebral cortex: 38.7,prostate: 6.9,Cell line enhanced,,Daudi: 11.3;MOLT-4: 36.1;SCLC-21H: 22.4;U-266/70: 20.1
357,JAKMIP2,"JAMIP2, KIAA0555",ENSG00000176049,Janus kinase and microtubule interacting protein 2,5,147585439-147782848,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046929, HPA065023",Approved,,Supported,Golgi apparatus,,Tissue enriched,Tissue enriched,6,cerebral cortex: 32.7,testis: 5.3,Cell line enhanced,,AF22: 19.7;Karpas-707: 34.1;RH-30: 46.3;SCLC-21H: 26.3
358,KCNA1,"AEMK, HUK1, Kv1.1, MBK1, RBK1",ENSG00000111262,Potassium voltage-gated channel subfamily A member 1,12,4909893-4918256,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,CAB022365,Uncertain,,,,,Not detected,Tissue enriched,6,cerebral cortex: 13.4,parathyroid gland: 2.1,Cell line enhanced,,SCLC-21H: 1.2;U-2 OS: 1.0
359,KCNA2,"HK4, Kv1.2",ENSG00000177301,Potassium voltage-gated channel subfamily A member 2,1,110519837-110631474,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,CAB001976,Enhanced,,,,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 23.2,thyroid gland: 4.1,Cell line enhanced,,Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6
360,KCNH1,"eag, eag1, h-eag, Kv10.1",ENSG00000143473,Potassium voltage-gated channel subfamily H member 1,1,210676823-211134180,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA014551, HPA019445",Enhanced,,Approved,Vesicles,,Not detected,Tissue enriched,6,cerebral cortex: 6.2,testis: 1.0,Cell line enhanced,,RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3
361,KIAA0319,NMIG,ENSG00000137261,KIAA0319,6,24544104-24646155,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA015607, HPA076313",Enhanced,,Uncertain,Vesicles,,Mixed,Tissue enriched,6,cerebral cortex: 15.8,fallopian tube: 2.8,Cell line enhanced,,HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
362,LINC00672,,ENSG00000263874,Long intergenic non-protein coding RNA 672,17,38925168-38929384,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enriched,6,cerebral cortex: 20.1,endometrium: 3.3,Cell line enhanced,,NTERA-2: 6.4
363,LIX1,"C5orf11, Lft",ENSG00000145721,Limb and CNS expressed 1,5,97091867-97142872,Predicted intracellular proteins,Evidence at transcript level,HPA058426,Uncertain,,Approved,Vesicles<br>Cytokinetic bridge<br>Cytosol,Endometrial cancer:2.48e-4 (unfavourable),Tissue enhanced,Tissue enriched,6,cerebral cortex: 32.8,seminal vesicle: 5.7,Cell line enriched,9.0,RPTEC TERT1: 24.5
364,MAG,"GMA, S-MAG, SIGLEC-4A, SIGLEC4A",ENSG00000105695,Myelin associated glycoprotein,19,35292125-35313804,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009345, HPA012499",Enhanced,,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 163.6,ovary: 27.5,Cell line enriched,31.0,WM-115: 35.4
365,MARCH4,"KIAA1399, MARCH-IV, RNF174",ENSG00000144583,Membrane associated ring-CH-type finger 4,2,216257865-216372027,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014348,Approved,,,,,Mixed,Tissue enriched,6,cerebral cortex: 9.1,stomach: 1.6,Cell line enhanced,,BJ: 63.3;fHDF/TERT166: 37.3
366,NACAD,KIAA0363,ENSG00000136274,NAC alpha domain containing,7,45080438-45088914,Predicted intracellular proteins,Evidence at protein level,HPA020981,Enhanced,,Approved,Nucleus<br>Cytosol,Glioma:2.23e-4 (unfavourable),Group enriched,Tissue enriched,6,cerebral cortex: 48.7,ovary: 7.6,Cell line enhanced,,SCLC-21H: 30.5;SH-SY5Y: 19.0
367,NMNAT2,"C1orf15, KIAA0479, PNAT2",ENSG00000157064,Nicotinamide nucleotide adenylyltransferase 2,1,183248237-183418602,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061714,Enhanced,,,,,Mixed,Tissue enriched,6,cerebral cortex: 73.5,testis: 13.3,Cell line enhanced,,SCLC-21H: 91.4;U-2197: 42.4;U-87 MG: 34.4
368,NOS1AP,"CAPON, KIAA0464",ENSG00000198929,Nitric oxide synthase 1 adaptor protein,1,162069774-162370475,Predicted intracellular proteins,Evidence at protein level,"CAB018582, HPA030066, HPA055561",Approved,,Approved,Nucleus<br>Vesicles,,Mixed,Tissue enriched,6,cerebral cortex: 23.4,adrenal gland: 3.8,Cell line enhanced,,A-431: 3.6;HEL: 4.5
369,NYAP2,KIAA1486,ENSG00000144460,Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2,2,225399710-225654018,Predicted intracellular proteins,Evidence at protein level,HPA045531,Uncertain,,Approved,Nucleoplasm<br>Intermediate filaments,,Not detected,Tissue enriched,6,cerebral cortex: 1.8,lung: 0.3,Cell line enhanced,,SiHa: 2.0
370,P2RY12,"HORK3, P2Y12, SP1999",ENSG00000169313,Purinergic receptor P2Y12,3,151337380-151384812,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA013796, HPA014518",Enhanced,,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 83.8,lymph node: 13.1,Not detected,,
371,PCDH11Y,"PCDH22, PCDHY",ENSG00000099715,Protocadherin 11 Y-linked,Y,5000226-5742224,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000432,Uncertain,,,,,Not detected,Tissue enriched,6,cerebral cortex: 4.4,"placenta,seminal vesicle: 0.7",Not detected,,
372,RIT2,"RIBA, RIN",ENSG00000152214,Ras like without CAAX 2,18,42743227-43115691,Predicted intracellular proteins,Evidence at protein level,HPA072174,Supported,,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 18.3,adrenal gland: 2.8,Not detected,,
373,SHD,,ENSG00000105251,Src homology 2 domain containing transforming protein D,19,4278601-4290724,Predicted intracellular proteins,Evidence at protein level,HPA017955,Uncertain,,Uncertain,Microtubule organizing center<br>Cytosol,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 22.1,heart muscle: 3.8,Group enriched,57.0,RH-30: 51.7;SH-SY5Y: 181.9
374,SLC25A22,"EIEE3, FLJ13044, GC1, NET44",ENSG00000177542,Solute carrier family 25 member 22,11,790475-798333,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA014662,Approved,,Enhanced,Nucleoplasm<br>Mitochondria,,Expressed in all,Tissue enriched,6,cerebral cortex: 89.6,testis: 15.2,Expressed in all,,
375,SPTBN4,"KIAA1642, SPTBN3",ENSG00000160460,"Spectrin beta, non-erythrocytic 4",19,40466241-40576464,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA054481,Enhanced,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enriched,6,cerebral cortex: 18.6,adrenal gland: 2.8,Cell line enhanced,,K-562: 1.6;Karpas-707: 1.8;SCLC-21H: 4.6;SH-SY5Y: 2.5
376,STMN2,"SCG10, SCGN10",ENSG00000104435,Stathmin 2,8,79610814-79666175,Predicted intracellular proteins,Evidence at protein level,HPA026922,,Supported,Approved,Endoplasmic reticulum<br>Vesicles,,Group enriched,Tissue enriched,6,cerebral cortex: 489.4,adrenal gland: 88.0,Cell line enriched,10.0,SH-SY5Y: 696.7
377,TMEM145,FLJ90805,ENSG00000167619,Transmembrane protein 145,19,42313325-42325062,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060462,Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 38.3,adrenal gland: 5.9,Cell line enhanced,,SCLC-21H: 32.9;SH-SY5Y: 14.2
378,TSPAN7,"A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2",ENSG00000156298,Tetraspanin 7,X,38561370-38688920,"CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA003140, CAB062566, CAB068245",Enhanced,,,,"Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable)",Expressed in all,Tissue enriched,6,cerebral cortex: 574.4,adrenal gland: 99.2,Cell line enhanced,,HDLM-2: 39.2;MOLT-4: 141.6;SCLC-21H: 109.6;U-266/70: 47.0
379,TTBK1,KIAA1855,ENSG00000146216,Tau tubulin kinase 1,6,43243680-43288259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031735, HPA031736",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 18.9,small intestine: 3.1,Group enriched,13.0,SCLC-21H: 24.9;SH-SY5Y: 8.7
380,TTYH2,C17orf29,ENSG00000141540,Tweety family member 2,17,74213514-74262020,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:9.74e-5 (unfavourable),Group enriched,Tissue enriched,6,cerebral cortex: 129.2,testis: 21.8,Cell line enhanced,,SK-MEL-30: 62.2
381,TUBB2B,"bA506K6.1, DKFZp566F223, MGC8685",ENSG00000137285,Tubulin beta 2B class IIb,6,3224261-3231730,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA043640, HPA046280",Supported,,,,Endometrial cancer:1.94e-4 (unfavourable),Tissue enriched,Tissue enriched,6,cerebral cortex: 308.7,epididymis: 51.8,Cell line enhanced,,AF22: 504.0;CACO-2: 319.1;SCLC-21H: 896.6;SH-SY5Y: 392.2
382,TUBB3,"beta-4, CFEOM3, CFEOM3A, FEOM3",ENSG00000258947,Tubulin beta 3 class III,16,89921392-89938761,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043640, HPA046280",Approved,,,,,Mixed,Tissue enriched,6,cerebral cortex: 195.6,adrenal gland: 34.5,Cell line enhanced,,SCLC-21H: 490.8
383,XKR4,KIAA1889,ENSG00000206579,XK related 4,8,55102389-55542054,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA025072, HPA028083",Uncertain,,,,,Not detected,Tissue enriched,6,cerebral cortex: 4.7,seminal vesicle: 0.8,Group enriched,9.0,REH: 2.3;RPTEC TERT1: 7.5
384,ZIC2,HPE5,ENSG00000043355,Zic family member 2,13,99981772-99986773,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055031,,,Supported,Nuclear bodies,"Cervical cancer:2.64e-4 (favourable), Liver cancer:2.91e-4 (unfavourable)",Mixed,Tissue enriched,6,cerebral cortex: 7.3,testis: 1.2,Cell line enhanced,,AF22: 84.4;HEK93: 60.2;NTERA-2: 79.9;SCLC-21H: 209.9
385,ACBD7,"bA455B2.2, FLJ38219",ENSG00000176244,Acyl-CoA binding domain containing 7,10,15077523-15088776,Predicted intracellular proteins,Evidence at protein level,"HPA043326, HPA062478",,,Approved,Vesicles<br>Cytosol,,Mixed,Tissue enriched,5,cerebral cortex: 40.5,testis: 7.7,Cell line enhanced,,MOLT-4: 29.4
386,AKAP5,"AKAP75, AKAP79",ENSG00000179841,A-kinase anchoring protein 5,14,64465499-64474503,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB004308, HPA053891",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enriched,5,cerebral cortex: 22.5,rectum: 4.2,Cell line enhanced,,CACO-2: 9.0
387,BEGAIN,KIAA1446,ENSG00000183092,Brain enriched guanylate kinase associated,14,100537147-100587413,Predicted intracellular proteins,Evidence at protein level,HPA002899,Uncertain,,Uncertain,Nucleus<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enriched,5,cerebral cortex: 20.0,adrenal gland: 3.8,Group enriched,8.0,HeLa: 36.4;SH-SY5Y: 137.4
388,C1QTNF4,"CTRP4, ZACRP4",ENSG00000172247,C1q and tumor necrosis factor related protein 4,11,47589664-47594659,Predicted secreted proteins,Evidence at protein level,HPA041032,Approved,,,,,Mixed,Tissue enriched,5,cerebral cortex: 28.2,parathyroid gland: 5.2,Cell line enriched,6.0,REH: 10.4
389,CDH20,"Cdh7, CDH7L3",ENSG00000101542,Cadherin 20,18,61333582-61555773,Predicted membrane proteins,Evidence at protein level,HPA015490,Uncertain,,,,,Tissue enriched,Tissue enriched,5,cerebral cortex: 26.8,adipose tissue: 4.9,Cell line enhanced,,AF22: 1.8;ASC diff: 3.9;HHSteC: 2.2;SH-SY5Y: 4.1
390,CHL1,"CALL, FLJ44930, L1CAM2, MGC132578",ENSG00000134121,Cell adhesion molecule L1 like,3,196596-409417,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003345, CAB026120",Enhanced,,,,Renal cancer:1.21e-6 (favourable),Tissue enhanced,Tissue enriched,5,cerebral cortex: 111.8,ovary: 20.9,Group enriched,6.0,SK-MEL-30: 73.7;WM-115: 29.2
391,COLGALT2,"C1orf17, GLT25D2, KIAA0584",ENSG00000198756,Collagen beta(1-O)galactosyltransferase 2,1,183929854-184037729,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031749, HPA031750",Approved,,Approved,Nucleus<br>Vesicles,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 46.4,prostate: 8.8,Cell line enhanced,,Hep G2: 11.7;SK-MEL-30: 14.3;U-251 MG: 14.6;WM-115: 22.1
392,CPNE9,KIAA4217,ENSG00000144550,Copine family member 9,3,9703807-9729908,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 12.6,testis: 2.3,Cell line enhanced,,Daudi: 1.6;U-937: 1.6
393,CRMP1,"DPYSL1, DRP-1",ENSG00000072832,Collapsin response mediator protein 1,4,5748084-5893058,Predicted intracellular proteins,Evidence at protein level,"HPA035640, CAB037313",Approved,,Supported,Centrosome<br>Cytosol,Pancreatic cancer:4.54e-4 (favourable),Expressed in all,Tissue enriched,5,cerebral cortex: 133.7,endometrium: 24.5,Cell line enhanced,,HAP1: 120.7;REH: 208.7;RH-30: 125.4;SCLC-21H: 196.8;SH-SY5Y: 112.2
394,DCLK1,"DCAMKL1, DCDC3A, DCLK, KIAA0369",ENSG00000133083,Doublecortin like kinase 1,13,35768652-36131306,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB012405, HPA015040, HPA015655",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:4.42e-4 (unfavourable),Tissue enhanced,Tissue enriched,5,cerebral cortex: 140.5,smooth muscle: 27.3,Cell line enhanced,,ASC diff: 19.8;ASC TERT1: 19.0;fHDF/TERT166: 18.2;HAP1: 18.4;HSkMC: 18.4;NTERA-2: 36.7
395,EPHA5,"CEK7, EHK1, Hek7, TYRO4",ENSG00000145242,EPH receptor A5,4,65319563-65670495,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 18.0,"cervix, uterine: 3.3",Cell line enhanced,,PC-3: 8.7;TIME: 10.3;U-138 MG: 25.1;U-2197: 14.6;U-251 MG: 17.0
396,GDI1,"FLJ41411, GDIL, MRX41, MRX48, OPHN2, RABGDIA, XAP-4",ENSG00000203879,GDP dissociation inhibitor 1,X,154436913-154443467,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012979, HPA049290, HPA057668",Enhanced,,Approved,Vesicles,"Colorectal cancer:3.83e-5 (unfavourable), Breast cancer:6.84e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 532.0,smooth muscle: 101.3,Expressed in all,,
397,HCN2,"BCNG-2, BCNG2, HAC-1",ENSG00000099822,Hyperpolarization activated cyclic nucleotide gated potassium channel 2,19,589893-617159,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,Renal cancer:6.99e-5 (unfavourable),Group enriched,Tissue enriched,5,cerebral cortex: 38.3,heart muscle: 7.0,Cell line enhanced,,A549: 27.1;MCF7: 21.7;U-138 MG: 20.0;U-87 MG: 40.9
398,HEPACAM,"FLJ25530, GLIALCAM, hepaCAM",ENSG00000165478,Hepatic and glial cell adhesion molecule,11,124919193-124936412,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA017613, CAB025486",Enhanced,,Approved,Vesicles,,Tissue enriched,Tissue enriched,5,cerebral cortex: 80.7,adipose tissue: 15.1,Cell line enriched,27.0,Hep G2: 18.8
399,IDS,SIDS,ENSG00000010404,Iduronate 2-sulfatase,X,149476990-149521096,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enriched,5,cerebral cortex: 435.8,epididymis: 86.8,Expressed in all,,
400,KANTR,"LINC01155, Spasm",ENSG00000232593,KDM5C adjacent non-coding transcript,X,53094145-53170914,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enriched,5,cerebral cortex: 2.3,bone marrow: 0.4,Not detected,,
401,KISS1R,"AXOR12, GPR54, HOT7T175",ENSG00000116014,KISS1 receptor,19,917287-921015,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071913,,,Supported,Vesicles<br>Plasma membrane,Renal cancer:3.33e-6 (unfavourable),Tissue enhanced,Tissue enriched,5,cerebral cortex: 1.2,"appendix,lymph node,placenta: 0.2",Cell line enhanced,,K-562: 14.0;RPMI-8226: 26.1;SCLC-21H: 8.9;SH-SY5Y: 21.3
402,LRFN2,"FIGLER2, KIAA1246, SALM1",ENSG00000156564,Leucine rich repeat and fibronectin type III domain containing 2,6,40391586-40587465,Predicted membrane proteins,Evidence at protein level,HPA076660,Enhanced,,Supported,Vesicles,,Not detected,Tissue enriched,5,cerebral cortex: 6.8,testis: 1.3,Cell line enhanced,,REH: 1.5;SH-SY5Y: 5.0
403,LRRTM3,,ENSG00000198739,Leucine rich repeat transmembrane neuronal 3,10,66926006-67099830,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,5,cerebral cortex: 22.6,ovary: 4.2,Cell line enhanced,,AF22: 1.9;HAP1: 5.7;NTERA-2: 1.2
404,MAP1B,"MAP5, PPP1R102",ENSG00000131711,Microtubule associated protein 1B,5,72107234-72209570,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009792, HPA022275",Enhanced,,Enhanced,Cytosol,Urothelial cancer:8.22e-5 (unfavourable),Tissue enriched,Tissue enriched,5,cerebral cortex: 187.6,smooth muscle: 36.8,Cell line enhanced,,TIME: 228.1
405,MAPK8IP1,"IB1, JIP-1, JIP1, PRKM8IP",ENSG00000121653,Mitogen-activated protein kinase 8 interacting protein 1,11,45885651-45906465,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA058921, HPA070332",,,Enhanced,Plasma membrane,Renal cancer:1.23e-11 (favourable),Expressed in all,Tissue enriched,5,cerebral cortex: 177.1,parathyroid gland: 33.1,Cell line enhanced,,SCLC-21H: 89.8
406,MLLT11,AF1Q,ENSG00000213190,"Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11",1,151057758-151068497,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA000540,Uncertain,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 122.5,parathyroid gland: 24.0,Cell line enhanced,,AF22: 129.2;SH-SY5Y: 151.4
407,NAP1L2,"BPX, MGC26243",ENSG00000186462,Nucleosome assembly protein 1 like 2,X,73212299-73214848,Predicted intracellular proteins,Evidence at protein level,"HPA054050, HPA057065",,,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Pancreatic cancer:5.41e-4 (favourable),Mixed,Tissue enriched,5,cerebral cortex: 90.1,"parathyroid gland,prostate: 17.8",Cell line enhanced,,EFO-21: 15.7;NTERA-2: 18.1;U-2197: 13.6;U-266/84: 21.9
408,NSF,SKD2,ENSG00000073969,"N-ethylmaleimide sensitive factor, vesicle fusing ATPase",17,46590669-46757464,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA003154, CAB009324, CAB013645, HPA071089",Enhanced,,Supported,Cytosol,,Expressed in all,Tissue enriched,5,cerebral cortex: 134.3,parathyroid gland: 25.6,Mixed,,
409,NSMF,NELF,ENSG00000165802,NMDA receptor synaptonuclear signaling and neuronal migration factor,9,137447570-137459334,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA044316,Enhanced,,Supported,Nucleoplasm,Renal cancer:1.85e-6 (favourable),Expressed in all,Tissue enriched,5,cerebral cortex: 189.6,duodenum: 36.2,Mixed,,
410,OR14I1,"OR5BU1, OR5BU1P",ENSG00000189181,Olfactory receptor family 14 subfamily I member 1,1,248681369-248682304,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,5,cerebral cortex: 3.4,prostate: 0.6,Not detected,,
411,PAK5,"KIAA1264, PAK7",ENSG00000101349,P21 (RAC1) activated kinase 5,20,9537389-9839041,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA020444,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enriched,5,cerebral cortex: 13.4,adrenal gland: 2.6,Group enriched,10.0,SCLC-21H: 5.6;SH-SY5Y: 1.8
412,PCDHGA10,PCDH-GAMMA-A10,ENSG00000253846,"Protocadherin gamma subfamily A, 10",5,141412987-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enriched,5,cerebral cortex: 28.0,placenta: 5.1,Cell line enhanced,,AF22: 14.4;T-47d: 18.5
413,PPFIA2,,ENSG00000139220,PTPRF interacting protein alpha 2,12,81257975-81759553,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 61.0,testis: 11.4,Group enriched,9.0,HAP1: 30.3;SCLC-21H: 11.7
414,PRKACB,PKACb,ENSG00000142875,Protein kinase cAMP-activated catalytic subunit beta,1,84078062-84238498,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010363, HPA029754, HPA071185",Approved,,Approved,Cytosol,"Renal cancer:1.89e-6 (favourable), Liver cancer:9.49e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 316.3,adrenal gland: 63.1,Mixed,,
415,PTPRN,IA-2,ENSG00000054356,"Protein tyrosine phosphatase, receptor type N",2,219289623-219309648,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007152, HPA007179",Enhanced,,Approved,Endoplasmic reticulum,Glioma:2.45e-7 (unfavourable),Group enriched,Tissue enriched,5,cerebral cortex: 183.1,adrenal gland: 35.0,Group enriched,8.0,U-2 OS: 70.1;U-87 MG: 244.6
416,RGS4,SCZD9,ENSG00000117152,Regulator of G-protein signaling 4,1,163068775-163076802,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA030802,,,Approved,Intermediate filaments,"Stomach cancer:1.92e-4 (unfavourable), Renal cancer:3.97e-4 (unfavourable), Glioma:4.33e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 289.2,adrenal gland: 54.0,Cell line enhanced,,LHCN-M2: 245.4;SH-SY5Y: 612.2;TIME: 986.1
417,SLC22A17,"BOCT, BOIT, NGALR",ENSG00000092096,Solute carrier family 22 member 17,14,23346306-23352912,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA002728,Uncertain,,,,"Pancreatic cancer:1.73e-4 (favourable), Stomach cancer:5.95e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 275.0,prostate: 52.6,Cell line enhanced,,AN3-CA: 35.6;SH-SY5Y: 46.8
418,TMEFF1,"C9orf2, CT120.1, H7365",ENSG00000241697,Transmembrane protein with EGF like and two follistatin like domains 1,9,100473113-100577636,Predicted membrane proteins,Evidence at protein level,HPA051501,Uncertain,,,,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 10.7,testis: 2.0,Cell line enhanced,,NTERA-2: 28.1;REH: 17.9;SCLC-21H: 28.0;SH-SY5Y: 16.8
